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“Contra vim mortis non est medicamen”* 
 
 
- Sigismund III Vasa on his deathbed 1632 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To nine thousand soldiers, 
slaughtered on the fields  
of Lund December 4th 1676 
 
 
 
 
   *" There is no medicine against the lethal power of dea

  
FÖRORD 
 
Den här avhandlingen har varit min trogna följeslagare under de senaste fyra åren. Den är 
resultatet av många roliga och lärorika diskussioner med handledare och forskningskollegor, 
åtskilliga möten, hundratals timmar i djurlaboratoriet och på forskningslaboratoriet, tjugo 
högskolepoäng med tillhörande tentamina, samt inte minst de senaste sex veckornas intensiva 
läsande och skrivande. Boken har följt med mig, såväl på semesterresor, som på ECMO 
uppdrag i norra Finland. Utan mina fantastiska handledare, Thomas, Björn, Janne och Micke så 
hade den aldrig blivit av. Många andra vänliga människor har också bidragit. Bokens och min 
relation har inte varit helt okomplicerad. Det har varit en väldigt roligt men också bitvis 
utmanande tid. Det har nu blivit dags att lämna min första och kanske enda bok vidare. Det är 
inte utan viss stolthet som jag färdig förklarar min avhandling och jag hoppas att den kommer 
att intressera dig.  
Som när ett älskat barn flyttar hemifrån. Svårt men skönt. 
Så är det med den här boken också. 
Trevlig läsning, 
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ABSTRACT 
Lifesaving or Life-threatening? 
If the worst thing happens, and you get seriously injured in an accident, your body has a 
pronounced ability to immediately stop bleedings and start the process of healing.  This unique 
capacity only works to a certain degree. Our body cannot by itself handle life-threatening 
bleedings from the heart, large blood vessels or severe injuries to highly vascularized organs. 
Transfusion of blood products, acute surgery and intensive care are necessary to support the 
body. In devastating injuries even this may not be enough and new ways of treating massive 
bleeding needs to be explored. Sometimes our body’s rescue system gets overloaded and starts 
to counteract the intended positive reaction. Excessive coagulation with a resulting occlusion of 
a blood vessel is one example. In that case anticoagulation is needed. Another example is if 
inflammation, the process necessary to start healing, derails. This may cause an overwhelming 
inflammation in the lungs that abolish their ability of saturating our blood. If the lungs take 
time off, a heart lung machine can buy time for the healing and save the life. A heart lung 
machine (ECMO) needs anticoagulation since the plastic tubings can cause clotting. 
Anticoagulation is associated with the risk of dangerous bleeding. If the system clots, and the 
machine shut down, a life saving procedure can suddenly change to a life-threatening situation.  
This Thesis highlights both sides of the hemostatic and anticoagulative coin. We have attacked 
the mentioned challenges from four different angles.  
In Article I venoarterial ECMO’s effect on central blood pressure was investigated. The 
reason for this is that we had found an unexpected effect of ECMO, during trauma 
resuscitation. A young girl’s severe liver bleeding suddenly could be controlled when ECMO 
was initiated because of lung failure. Swine were used in the study and we found that VA 
ECMO reduced the central venous pressure while mean arterial pressure was improved. 
In Article II a novel way of anticoagulation or “thromboprotection” in an ECMO system was 
evaluated. 3F7, an antibody that inhibits the activated form of coagulation factor XII was 
studied on rabbits connected to ECMO. 3F7 could prevent clotting in the ECMO system as 
effective as heparin but did not impair the hemostatic capacity and did not increase wound 
bleedings.  
In Article III venoarterial ECMO’s effect on rabbits in lethal traumatic bleeding shock was 
evaluated. Focus was on how the ECMO treatment affects central circulation, temperature, 
acid-base balance and the coagulation ability. ECMO efficiently increased the temperature, 
stabilized the circulation, improved the pH and ameliorated the hemostatic capacity. 
In Article IV Polyphosphate (PolyP), a substance that is released from activated platelets and 
that induces coagulation by activating FXII was investigated. Liver injuries in swine were 
treated with PolyP, Kaolin and a non-active substance. PolyP efficiently initiated thrombin 
formation and terminated bleeding as efficiently as Kaolin but with less inflammation. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppsskador i samband med olyckor och våld är ett allvarligt problem, inte bara för den 
enskilda individen och dennes anhöriga, utan även för samhället. Det är huvudsakligen unga 
människor i arbetsför ålder som drabbas av svåra skador och i åldern 5-45 år är trauma den 
vanligaste dödsorsaken. Förutom den svåra psykosociala påfrestningen, det innebär för 
drabbade familjer, så uppgår kostnaderna för samhället till miljardbelopp för vård och förlorad 
arbetskraft. Under de senaste decennierna har omhändertagandet av svårt skadade patienter 
förbättrats avsevärt. Genom Advanced Trauma Life Support (ATLS) kurserna, som initierades i 
USA i början av 1980-talet och som successivt förbättrats och spridits internationellt, har det 
initiala omhändertagandet blivit allt mer strukturerat. Den traumakirurgiska kompetensen på 
sjukhus runt om i världen har också stärkts genom Damage Control Surgery- och Definitive 
Trauma Surgical Care utbildningar. Det har blivit alltmer uppenbart att den svårt skadade 
patienten, efter akut åtgärd av livshotande luftvägs- och blödningsproblem, behöver en 
normaliserad fysiologi snarare än en perfekt återställd anatomi. Kunskaper och erfarenheter 
vunna från krigs- och katastrofområden, med många allvarligt skadade under kort tid, 
implementeras i den civila sjukvården och civila tekniker och utrustningar flyttas närmare 
stridsfältet. En ledstjärna i modern traumavård är att inte åstadkomma mer skada än nödvändigt 
vid en kirurgisk behandling, s.k. minimal-invasiv kirurgi. Detta för att den redan skadade 
kroppen inte ska belastas ytterligare Ett bra exempel på det är blodkärlsröntgen, s.k. angiografi, 
där blödningar i olika organ kan stillas på ett enkelt och skonsamt sätt. Trots stora förbättringar 
av traumavården dör fortfarande alltför många människor efter trauma och nya obeprövade 
behandlingssätt behöver identifieras och utvärderas.  
Extracorporeal Membranoxygenering (ECMO) är en behandling som vidareutvecklats från 
hjärt-lung maskin behandling (CPB) och som sedan början av 1980-talet används för att stödja 
hjärt- och lungfunktion på intensivvårdspatienter där konventionell behandling inte är 
tillräcklig. ECMO är traditionellt inte använt vid behandling av skadade personer även om 
sporadiska fallrapporter där behandlingen använts i det akuta skedet till döende patienter efter 
trauma förekommer. Det finns dock endast en tidigare känd djurstudie där ECMOs effekt vid 
blödningschock undersökts och då utvärderades effekten av djup nedkylning. Vissa fördelar 
med ECMO vid trauma är logiska och enkla att förstå. Både hjärt- och lungfunktionen kan 
stödjas på ett säkert sätt. De grova kanylerna tillåter snabb ersättning av stora mängder 
blodprodukter, blodet kan värmas, syresättas och renas från koldioxid. Kroppsorgan, som t.ex. 
levern och lungorna, kan kopplas ur cirkulationen vilket medger reparation av dessa organ utan 
att patienten blöder ihjäl och med bibehållen systemcirkulation.  
I det här doktorsavhandlingsarbetet har vi undersökt vilka för- och nackdelar ECMO- 
behandling kan ha i det allra mest akuta omhändertagandet av skadade. Vi har valt att arbeta 
med gris- och kanin modeller på grund av att de är väldigt lika människor både anatomiskt och 
fysiologiskt. Dessa djurs koagulationssystem är också nästan identiska med människans. Det är 
mycket viktigt att poängtera att alla djur har varit djupt sövda, inte har kunnat uppleva försöken 
och inte har känt någon smärta. Under alla försök har specialutbildade djurskötare kontrollerat 
djuren och i alla kaninförsök har en veterinär deltagit.  
 I korthet har vi undersökt vad som händer med blodtrycken i kroppens centrala blodkärl och 
blodets koagulationsförmåga vid ECMO-behandling. Det visade sig att det centrala 
venblodtrycket sänktes signifikant samtidigt som artärblodtrycket förbättrades. Detta kan ha en 
positiv betydelse i samband med svåra skador och underlätta kontroll av blödningar som är 
svåra att hantera kirurgiskt. I en annan studie utsattes sövda kaniner för lårbensbrott och blödde 
45 % av blodvolymen. ECMO-behandlingen höjde effektivt kroppstemperaturen, förbättrade 
den centrala cirkulationen, minskade blodets surhet och förbättrade koagulationsförmågan. 
Vidare undersöktes ett helt nytt sätt att blockera blodets levringsförmåga utan att öka 
blödningsrisken. Detta har inte tidigare lyckats med några andra kända läkemedel. Det gjordes 
genom att koagulationsfaktor XII (FXII) blockerades med en antikropp (3F7). Resultatet blev 
ett effektivt skydd mot blodpropps-bildning i ECMO-systemet och med bibehållen 
koagulationsförmåga. Eftersom konceptet att blockera FXII systemiskt fungerade väl, så blev 
nästa steg att istället aktivera FXII lokalt. Det gjordes för att uppnå den motsatta effekten, det 
vill säga stoppa blödning, i leverskador på gris. Polyphosphat, en substans som normalt finns i 
kroppens blodplättar, de blodkroppar som deltar i koagulationen, användes. Polyphosphat 
består av linjära molekylkedjor av fosfatjoner (PO42-). De är kraftigt negativt laddade molekyler 
som aktiverar FXII. Leverblödningarna upphörde effektivt och polyphosphat orsakade ingen 
nämnvärd inflammation. Dessutom bröts det ned av kroppsegna enzymer och var efter 4 dygn 
inte längre påvisbart i blodet.  
  
 
 
De viktigaste slutsatserna av studierna är: 
 
I. ECMO sänker det centrala venblodtrycket samt bibehåller eller förbättrar 
artärblodtrycket. 
  
II. Blockering av FXIIa förhindrar på ett säkert sätt koagulering i ECMO-
system utan ökad blödningsrisk. 
  
III. ECMO förbättrar koagulationsförmågan efter livshotande blödningschock. 
 
IV. Polyphosphat skapar effektiv blodstillning i leverskador. 
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1. INTRODUCTION 
History of Trauma Surgery  
Karl the XI 1, 2 
       
Karl X Gustav (1622-1660)             Karl XI  (1655-1697)                 Ulrika Eleonora (1656-1693)          Lorentz Creutz (1615-1676) 
Karl XI was born on November 24, 1655 at the Royal Castle, Tre Kronor in Stockholm. Karl 
was crowned as Sweden’s King 1660, only 4 years old, at the death of his father, Karl X 
Gustav. Doctor Emporagrius prescribed bloodletting to the King and the nature of the blood 
told him that his Majesty was in a very bad condition. In the night on the 13th of February, 
between one and two, Karl X Gustav expired of pneumonia and sepsis. The little boy was left 
with a country at its peak. Sweden was after France the second largest and richest country in 
Europe. Sweden had conquered several landscapes from Denmark in 1658, confirmed by the 
Roskilde peace treaty, and the commanders were rewarded with land. Magnificent castles were 
built (e.g. Läckö by Magnus Gabriel De la Gardie, Skokloster by Karl Gustav Wrangel and 
Drottningholm by the widow Queen Hedvig Eleonora). A guardian regency administered the 
country until the parliament declared that Karl at 17 was of age to control the nation. Great 
confidence was put on the young King and he was to be taught Latin, French, German, History, 
Astronomy, Geography, Art and the Art of War. If Louis the XIV of France was the “Sun 
King”, Karl was to become the “North Star”. To the regency’s disappointment Karl was 
dyslexic, had writing difficulties, and a fragile health so the Queen favored riding and hunting 
for him instead of theoretical studies. Karl preferred to spend time with his family and close 
friends at a small mansion in Kungsör. The Swedish regency had tied a close relationship with 
France but had ongoing conflicts with Denmark, Holland, Brandenburg and Poland. Karl tried 
to reach a neutrality covenant with the Danish King, Christian V, but was dismissed. The 
diplomat Niels Brahe was sent to Copenhagen in June 1675 with a portrait of the King and 
proposed on Karl’s behalf to Ulrika Eleonora (Christian’s sister). Ulrika Eleonora instantly fell 
in love and Christian initially agreed, but during the coming war he changed his mind. At that 
time the betrothal had already concluded and engagement rings were exchanged. Ulrika refused 
to break the engagement, and she even pawned her own engagement ring to be able to buy 
medicine and food for Swedish prisoners. In Sweden, the Lutheran Church held witch trials 
and more than 300 innocent young women were executed and burned at the stake. False 
testimonies of witchcraft often came from young children. Governor Lorentz Creutz was the 
chairman in the sorcery tribunal “Trolldomskomissionen” in Mora 1669 and sentenced more 
than 20 women to death. There was horror in the country and a growing threat from abroad.  
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The Battle of Lund 3, 4 
            
Karl XI at the Battle of Lund 4:th Dec 1676 (J. F. Lemke)          Karl XI (D. K. Ehrenstrahl)                   Christian V of Denmark (Unknown artist) 
In September 1675 King Christian V proclaimed war against Sweden just three months after 
his sister’s engagement with Karl. Denmark wanted back the rich eastern provinces of Skåne, 
Blekinge, Halland, Bohuslän, Jämtland, Härjedalen and Gotland. The Swedish Navy sailed in 
May 1676 under command of the new Admiral Creutz, the same Creutz who had sent innocent 
young women to death seven years earlier. He was well known in the parliament but had no 
experience of the sea. Creutz led the armada on ”Kronan”, the largest warship ever built in 
Sweden (twice the size of the Royal Ship Wasa). Kronan carried 850 men and was armed with 
125 bronze canons. Another 34 large warships followed her. The Navy’s task was simple: “find 
and wipe out the Danish Navy”. On June 1st 1676 they met the Danish and Dutch fleets outside 
the south cape of Öland. It all became a disaster. Admiral Creutz ordered a sharp turn with open 
gun slots, water flooded in, Ronan had a list and an ignition fell into the powder storage and the 
whole ship exploded. It must have been an unthinkable but glorious moment for the Danish 
admiral to watch the Swedish crown Jewel, one of the biggest warships in the world, explode 
without a single shot being fired. Maybe it was also a bittersweet revenge for the relatives of 
the young executed women when Commander Creutz with all his men drowned. With one 
exception all the other Swedish ships fled north. Several ships sank and 3000 dead sailors 
remained in the sea outside Öland. Now it was easy for the Danish troops to invade the island 
and then the mainland. Christian disembarked an army of 15000 men south of Helsingborg on 
June 29th. King Karl was furious when he realized what had happened and put all his advisors 
aside and took command of the National Defense himself. New regiments were set up and 
equipped in each county. This was the foundation of the Karolinska Army. Late in the fall of 
1676 the Danish Army had regained Gotland, the major part of Skåne, Halland and Bohuslän 
and the Swedish troops were retreated to Småland. The guerilla of Salad “Snapphanarna” was 
educated by the Danish army to fight behind the lines and cut the enemies support. The Danes 
burned villages and farms. The Swedes were starving and many soldiers were in a critical 
condition. In November Karl reached the river Kävlingeån. All the bridges were destroyed, the 
shores were flooded due to heavy rains and the Danish Army was impossible to reach, located 
just a few kilometers south at Svenstorp’s Castle. Was Karl to loose Skåne to Denmark 
forever? After two weeks of rain Karl was suddenly saved by the cold winter. Kävlingeån froze 
and field marshal Erik Dahlberg assessed the frozen ice to be strong enough to carry the heavy 
armed horses and artillery.  Karl had to choose between Victory and Death.  
  4 
He wrote to his mother that, if killed, he wanted to be buried in the Riddarholmen’s Church 
together with his ancestors and at midnight the 4th of December he confessed to Archbishop 
Haquin Spegel. Three in the morning, just after the moon had disappeared, the King and the 
Swedish army with 8000 soldiers crossed the frozen river. The Danish troops had been partying 
the night before and did not react until seven in the morning when the Swedes were a few miles 
away. 13000 drowsy and hangover Danish soldiers tried to organize. Karl realized that the 
battle was better fought near the town of Lund so he started to move the troops there. 
Meanwhile Christian also moved his troops in parallel. All were racing towards Lund. The 
Swedes won the race and took place first. The battle began at 9 am. Karl’s horse was shot in the 
head but he got the white horse Brilliant (a gift from the French King) instead. The Danish 
Supreme commander was injured early and together with King Christian they fled north 
followed by King Karl and his troops. They were followed up to Kävlingån but now the ice had 
thawed. Christian and his son Prince George landed safely on the other side but hundreds of 
Danish soldiers drowned. Meanwhile the Karoliner Army was badly beaten by the Danes at 
Lund. Karl should not have left his troops. Erik Dahlberg rode up the King and convinced him 
to come back to Lund. When the Danish saw the King coming back they thought he was the 
vanguard to troop reinforcement and that they were attacked from two sides simultaneously.  
The right wing with 5 squadrons from Livregementets Husarer and the third cavalry regiment 
(today K3), was led by Colonel Nils Bielke and they were particularly successful. The Danes 
were shattered, fled and the final battle became a massacre of Danish and Dutch soldiers 
outside Vallkärra Church. The Surviving Danish troopers fled to the Landskrona Church where 
they were safe. For more than 18 hours the King and his men had been at horse fighting 
without food or water. When the night fell the victorious King Karl knelt down and 
accompanied by a thousand death cries from men and horses, Archbishop Spegel held a speech; 
”Skåden de många tusende, som på fälten runt omkring eder ligga kalla och stelnade i den 
eviga sömnen! Hören från när och fjärran jämmerskriet av de många tusenden, som likaledes 
runt omkring oss ligga sargade i plågor och dödskval. Att icke I liggen i detta ögonblick på 
samma sätt kvidande i dödsångesten, eller stelnade i döden, det är icke eder förtjänst, icke edert 
mod, icke eder skicklighet. Det är Guds hjälp, som hjälpt eder, hans nåd och barmhärtighet som 
förbarmat sig över eder och från edra huvuden avvänt de många tusende hotande faror.”5 This 
was one of the bloodiest days in war history. More than 9000 soldiers from different countries 
were killed on a single day. More casualties, than during D-Day in World War II. The 21-year-
old King would never forget this day. He had overcome his timidity and taken command of the 
confused Swedish soldiers and extinguished the Danish Army. He would never forget the blast 
waves of grenades exploding, the vision of dying friends and the sound of injured horses. This 
was the turning point of the war and Skåne was never to become Danish again. This was the 
baptism of fire for the Karoliner Army and it was together with other wars around the world the 
birth of modern trauma surgery.  
 
 
This Thesis is dedicated to the thousands of soldiers killed on the 4th of December 1676 
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Swedish surgeons, Uppsala University and Karolinska Institutet 6, 7 
                     
François Du Rietz (1607-1682)     Olof Rudbeck (1630-1702)                   Olof af Acrel (1717-1806)                    Karl XIII (1748-1818) 
Swedish surgeons 
The barber-surgeons were the first surgeons. They were barbers mainly from Germany and 
combined cutting hair and beard with bloodletting, tooth extraction and emptying of 
abscesses. In war times they were recruited to the army and in Sweden called ”fältskärerna”. 
Queen Christina’s livmedicus barber-surgeon Balthasar Salinus came from Danzig in 1611. 
He was the first man to perform documented surgery in Sweden. The barbers at the Royal 
Court were to become responsible for the military healthcare and in 1613 it was decided that 
each regiment should have one barber-surgeon and four journeymen ”gesäller”. In Germany 
the titles barbiere und bardscherer were changed to ”Chirurgen” and from 1647 Salinus was 
called Royal Surgeon ”Kunglig Kirurg”. Salinus’ both sons Carl and Magnus followed their 
father and both worked for Karl XI. At the Battle of Lund brave soldiers were forced to meet 
the enemy eye-to-eye with guns, sabres and knifes. They knew that if seriously injured the 
chance of survival was almost none and there were only five men with ”medical training” per 
Regiment (1200 soldiers). With knifes, scissors, branding irons, saws and trepanation-drills, 
injured soldiers were operated with only aquavit as the sedative.  Gunshot wounds could be 
treated with amputations if located in an arm or a leg. Boiling oil was poured on the 
amputation wound to stop the bleeding.  Penetrating injuries to the thorax and abdomen had 
to be left untreated. This commonly resulted in empyemas and peritonitis, meaning a 
torturous death. To spare dying soldiers suffering, mercy killings were common. Greatest 
chance for survival had soldiers with shallow wounds, but only if the wounds were cleaned 
and tetanus, gas gangrene and wound diphteria could be avoided.  
Uppsala University 
Uppsala University, the oldest one in the Nordic countries, was founded as early as 1477. The 
Medical education was delayed almost 200 years. In 1656 there were 1294 students of whom 
only 1 (sic!) studied medicine and in 1663 there were only 12 doctors in the entire country. 
Olof Rudbeck, who was the first to discover the lymphatic system, defended the thesis De 
Circulatione Sanguinis in 1652. He initiated anatomy education in Uppsala and was 
nominated professor of medicine. In 1662 he became the principal of Uppsala University and 
helped the University to bloom. Olof Rudbeck was also an ancestor of Alfred Nobel, the 
founder of the Nobel Prize 
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Karolinska Institutet 
Grégoire François Du Rietz was the initial livmedicus (personal physician) of Karl XI. He 
founded ”Collegium Medicum” 1663 to settle the physician’s activities and limit quackery. 
Karl XI early understood the importance of trauma care and issued a Royal decree that all 
Swedish cities were obliged to have surgeons in 1680. Barber-surgeons had a bad reputation 
and to improve there knowledge and status the King initiated a test at ”fältskärsämbetet” in 
Stockholm and Magnus Balthasar Salinus founded the Surgical Society ”Kirurgiska 
Societeten” in 1686.  There were constant conflicts between the academic educated Medical 
Physicians and the more practically educated Surgeons. Urban Hjärne who had studied 
medicine under Olof Rudbeck became Karl XI:s  livmedicus in 1684. Hjärne was also a poet 
and is to have said; My son watch out for three things: for old hores, for red wine and for new 
doctors! Hjärne is mainly famous for finally stopping the witch processes and execution of 
innocent women in Stockholm 1676. Karl XI, only 42 years old, died of a spread pancreatic 
cancer in April 5th, 1697. Hjärne was the most well-educated physician in Sweden, but there 
was nothing he could do to help his King.   
In the beginning of 1700 a group of well-educated barber-surgeons came to Sweden. Olof af 
Acrel ”The father of Swedish Surgery” had studied at Uppsala University and came 1735 to 
Stockholm to learn surgery by one of the barber-surgeons, Gerhard Boltenhagen. After his 
initial training he spent 5 years studying at Universities in Germany and France and got 
inspiration from hospitals in England and Switzerland. In 1743 he enlisted the French Army 
and soon became acting Chief Surgeon in Lautersburg. When he came back to Sweden he 
was elected a member of Kirurgiska Societeten. His thesis Wound Characteristics was the 
first Swedish thesis in Surgery 1745. When Stockholm’s first Hospital ”Serafimerlasarettet” 
was opened in 1752 Acrel became the Chief Surgeon. Acrel strongly contributed to improve 
the relations between surgeons and physicians and the Medical Faculty at Uppsala University 
awarded him a doctorate of medicine in 1760, thus making him the first medico-chirurgus in 
Sweden. Acrel who had worked unwaged at Serafimerlasarettet for 24 years was offered a 
gift of 1000 riksdaler Silver but refused to accept it. Instead he donated the money for 
improvements in health care. Olof af Acrel died in 1806. Four years later, Acrels intentions 
were completed, when Collegium Medicum and Kirurgiska Societeten were fused. Carolinska 
Institutet was founded, by King Karl XIII, the 13th of December 13 1810, due to the high 
mortality in the field hospitals during the Swedish-Russian war 1808-1809. It was first named 
“Academy for the training of skilled army surgeons” or “Institut för danande av skickelige 
fältläkare” and was situated at the Royal Bakery on Riddarholmen, a small island in central 
Stockholm.                  The illustration below is Serafimerlasarettet in 1752. 
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Trauma Surgery from ancient Egypt to the 21:th Century7-9 
As long as man has existed on earth, attempts to heal wounds have likely been made. It is 
known that the Egyptians knew how to evacuate blood from traumatic brain injuries 10000 
years ago. They could also perform amputations, treat fractures, improve coagulation with 
raw meet and avoid wound infections with honey. During the millennia to come injuries to 
humans and wars around the world have forced physicians to continuously develop and 
improve trauma care. Medicine is probably the only field that has gained something from 
warfare. Below are listed important landmarks in medicine, surgery and trauma care.  
Milestones in Medicine, Surgery and Trauma Care 
Year Surgeon/Inventor Country Contribution 
1600 BC The Edwin Smith Papyrus   Egypt Suture of wounds, trepanation 
1550 BC The Eber’s Papyrus  Egypt Topical treatment. Raw meat-hemostasis  
1100 BC Huang Ti  China Anesthesia with opium and wine 
600 BC The Sushruta Samhita India Operations, instruments and cleanness 
450 BC Buddha  India The first known hospital 
400 BC Hippocrates  Greece 72 Medical books, CuSO4 -hemostasis  
200 BC Erasistratos  Greece The first known human dissection 
162 Galenos  Greece Surgery for gladiators 
900 Rhazes  Iraq Cautery. Catgut suture 
1170 Ruggierio Frugardi Italy Practica Chirurgie. Bowel suture 
1363 Guy De Chauliac France La Grande Chirurgie 
1379 John Arderne  England Treatesis of fistula-in-ano 
1460 Heinrich Von Pfolspeundt Germany Cauterizing GSW 
1477 Jacob Ulvsson  Sweden Uppsala University is founded 
1517 Hans von Gersdorff Germany War surgery illustrations. Opium 
1543 Andreas Vesalius Italy De Humani Corpori Fabrica (Anatomy) 
1545 Ambroise Pare´  France Ligature, Tourniquet 
1571 Johan III  Sweden The rights for Barber-surgeons 
1628 William Harvey  England The Heart and Blood circulation 
1663 François Du Rietz Sweden The Swedish Collegium Medicum 
1666 Richard Lower  England Blood transfusion 
1672 Richard Wiseman England Vascular surgery 
1686 Magnus Salinus  Sweden The Swedish Surgical Society 
1741 Carl von Linneʹ′  Sweden Professor in Medicine Uppsala 
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1750 John Pringle  England Military Medicine and Red Cross 
1759 Olof af Acrel  Sweden Chirurgiske Händelser 
1765 John Morgan  USA The first American Medical School 
1783 Antoine de Lavoisier France Lung function 
1794 John Hunter  England Blood, Inflammation, Prim.-Sec. healing 
1797-1815  Larrey (Napoleon’s Surgeon) France  Flying Ambulances. Amputations 
1810 Karl XIII  Sweden Karolinska Institutet is founded 
1831 Tomas Latta  England Saline i.v. Cholera-hypovolemia 
1846  William T. G. Morton USA Ether anesthesia 
1847 James Simpson  Scotland Chloroform anesthesia 
1847 Ignaz Semmelweis Hungary Chlorinated handwash  
1850  Louis Pasteur  France Bacteria. Pasteurization, vaccination 
1850 Theodore Billroth Germany The Father of modern abdominal surgery 
1855 Florence Nightingale England Improved standard in Military hospitals 
1860 Jules-Emile Pean France Surgical Hemostat (Peang)  
1860 Rudolph Virchow Germany Pathology of Hemorrhagic Shock 
1867 Joseph Lister  Scotland Antiseptic Surgery (Lancet) 
1877 Robert Koch  Germany Bacteriology, Sterilization 
1894 Ludwig Rehn  Germany First Heart Wound Repair 
1895 Conrad Roentgen Germany X-Ray 
1897 Nicholaysen  Norway Intramedullar fixation of Femur fractures 
1901 Landsteiner  Austria Discovery of bloodgroups A, B, O 
1902 Theodore Kocher CH International Society of Surgery 
1904-1905 Princess Gedroitz Russia 183 Laparotomies. Russian-Japan War 
1916 J. McLean  USA Heparin 
1914-1918 WWI George Crile USA Saline i.v hemmorhagic-hypovolemia 
1923 Berberich, Hirsch Germany Angiography   
1929 Alexander Fleming England Penicillin 
1930 John Gibbon  USA First ECMO system 
1939-1945  W W II: Blood transfusion. Antibiotics. Delayed wound closure. Faster transports to care. 
1950 Allgöwer, Mueller Germany AO Fracture System 
1953 John Gibbon  USA First Open Heart Surgery with CPB 
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1950-1953 Korean Conflict  USA-Korea MASH. Rapid Helicopter Evacuation 
1952 Frank Spencer  USA Vascular repair, Arterial Homograft 
1952 Michel De Bakey USA Surgery in World War II 
1955-1975 Vietnam War  USA  Hemodialysis. Mechanical Vent. Blood gas 
1967 Christiaan Barnard ZA  First human-human Heart Transplant 
1971 Kristensen  Germany Ultrasound Splenic Trauma 
1972 Cormack, Hounsfield ZA, England Computed Tomography 
1972 Lauterbur, Mansfield USA Magnetic Resonance Imaging 
1971 Hill  USA First surviving Trauma on ECMO 
1975 Bartlett  USA First Newborn on ECMO 
1980 ACS COT  USA Advanced Trauma Life Support 
1987 IATSIC: International Association for Trauma Surgery and Intensive Care 
1991 Operation Desert Storm USA-Iraq Intercontinal Eromedical Transfer 
1993 IATSIC ZA, CH, USA, CA, AU Definitive Surgical Trauma Care 
 
Severe injury is the leading cause of death in young adults. Trauma accounts for 4 million 
deaths per year (10000/day) and 1 million occur in Europe10. Injuries mainly affect people in 
working ages and trauma is after HIV the second most common cause of death in the 5-45-
year-old group11. For every person killed in injury, several thousands of injured patients 
survive. Many of them live with permanet disabling sequele. Cervical spine injuries and aortic 
ruptures are examples of injuries causing immediate death at the scene. Respiratory failure and 
bleeding shock are life-threatening complications after trauma and uncontrolled bleeding is the 
reason for 30% of trauma-related deaths12. Knowledge, experiences and technological 
advances in trauma care have been gained especially from WWI and later. Early triage and 
resuscitation affects outcome and trauma resuscitation has been improved during the last 20 
years. The concepts and courses of ATLS13, DCS14 and DSTC 15 described on page 35-36 all 
have contributed to an essential improvement in the care of severely injured patients. 
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The Hemostatic System16 
Humans and other vertebrates have a circulatory system with a heart, blood vessels and blood. 
During millions of evolutionary years nature has developed a protection- and healing 
mechanism for this circulatory system. The hemostatic system makes healing of injured blood 
vessels possible with preserved circulation and is arranged in the primary and secondary 
hemostasis. In mammals blood coagulation depends on more than twenty extracellular proteins, 
acting in a protease cascade. Every millisecond in every blood vessel, from the large aorta to 
the smallest capillaries, there are millions of pro-coagulant and anti-coagulant actions occurring 
to maintain a perfect balance of damage control and intact circulation. This balance depends 
upon three major players that interact with each other. The players are Platelets, Coagulation 
Factors and Endothelium.  
Primary hemostasis-Platelet plug  
Platelets (PLT) are discoid enucleate cells produced in the bone marrow and that circulates in 
the blood. They have different surface receptors and several storage granules and are key-
players for maintaining intact vascular walls and hemostasis. Immediately after an injury to a 
blood vessel, vasoconstriction and platelet aggregation occurs. Platelets follow a consistent 
pattern, adhesion, activation, secretion of active substances and aggregation. Exposed collagen 
and von Willebrand Factor (vWF) on the injured vessel wall lead to platelet adhesion. vWF 
connects the platelet to collagen through glycoprotein (GP) receptors on the platelet.  Platelets 
aggregate to an initial thrombus, change in shape, and secrete signalling substances, 
Thromboxane A2 (TXA2), Serotonin, Adenosine Diphosphate (ADP), Platelet Derived Growth 
factor (PDGF) and Polyphosphate (PolyP) from dense bodies and α-granule with vWF, FV, 
FXIII and fibrinogen. ADP, vWF and fibrinogen increase adhesion and aggregation of more 
platelets. TXA2 and serotonin contract the blood vessels and reduce blood loss. PDGF increase 
cell proliferation in angiogenesis, the formation of new blood vessels. Prostacyclin (PGI2), 
Heparansulfate (HS) and Nitric Oxide (NO) from uninjured endothelium makes the vessel non-
adhesive. The platelets create a binding surface upon which the coagulation cascade proceeds. 
Thrombin activates the platelets and Factor V, PolyP and fibrinogen accelerate coagulation 
(Fig. 1). 
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Figure 1. The primary hemostasis-platelet plug. Platelets contribute to  
hemostasis and act in four different stages. Adhesion, activation, secretion  
and aggregation. 
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Secondary hemostasis-Coagulation 
To secure and strengthen the platelet-plug, there is a need for reinforcement with fibrin-strands 
(coagulation). Fibrin is formed through a cascade reaction of plasma proteins, serin proteases, 
also called coagulation factors (F). Most coagulation factors are synthesized in the liver and 
circulate in plasma mainly in inactive forms (e.g. 1-2 % of FVII is active in uninjured humans). 
Activated thrombocytes, endothelial cells and monocytes contribute to the coagulation. 
Traditionally the coagulation system has been divided in the Tissue Factor- or extrinsic 
pathway and the contact- or intrinsic pathway. The contact pathway is initiated by contact 
between negatively charged ions and the zymogen FXII and is not considered to contribute to 
hemostasis. Coagulation in mammals is mainly initiated by FVII binding to exposed Tissue 
Factor (TF) on injured blood-vessel walls and the extrinsic pathway is the key to hemostasis 
after vessel injury. The extrinsic and intrinsic pathways leads to the common pathway were 
activated FX cleaves prothrombin to thrombin and thrombin in turn converts fibrinogen 
creating the Fibrin clot. In the presence of fibrin, thrombin activates FXIII and activated FXIII 
(FXIIIa) reinforces the fibrin clot by crosslinking the fibrin polymers. Coagulation factors acts 
as enzymes or cofactors. Ca2+ and phospholipids are important for most of their reactions. 
Thrombin (FIIa) is the central enzyme in the coagulation cascade. Thrombin activates 
coagulation through several coagulation factors but also induces the anticoagulant pathway 
through protein C, protein S and fibrinolysis. The initial formation of TF: FVIIa complex 
generates a small amount of thrombin. This thrombin ”burst” is essential for hemostasis and 
feed back activates platelets, FV, VIII, X and XI, which generate more FIIa (Fig. 2). 
    
 
Figure 2. The Coagulation Cascade. Creation of a fibrin clot (low left).  
The intrinsic, extrinsic and common pathways are indicated (black arrows).  
Thrombin’s feed back activation (green). AT III, TFPI and APC inhibition (red). 
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The Endothelium  
The endothelium is the inner layer of a blood vessel and it promotes blood fluidity as long as 
there is no injury to the vessel wall. In case of damage the endothelium promotes coagulation 
but prevent thrombosis. The endothelium has both pro-coagulant and anti-coagulant properties 
(Fig.3). 
Procoagulant  
If the vessel wall is injured Tissue factor (TF) a glycosylated trans-membrane protein is 
exposed on the surface of the vascular wall. TF binds to FVIIa and is the major activator of the 
extrinsic system of coagulation. The complex of TF: FVIIa activates FIX and FX that activate 
prothrombin (FII) to thrombin (FIIa). Endothelial cells are major producers of von Willebrand 
Factor (vWF), a large protein, working as a intercellular glue that binds platelets to each other 
and to subendothelial matrix at injury sites. vWF also act as a carrier for FVIII. vWF binds to 
platelet glycoprotein (GP) receptor and mediates platelet adhesion. Platelet Activating Factor 
(PAF) is produced both in endothelial cells and in platelets. PAF induces platelet aggregation 
and degranulation. The endothelium also inhibits the fibrinolytic system through activation of 
Thrombin activatable fibrinolytic inhibitor (TAFI) and Plasminogen activator Inhibitor (PAI). 
Thrombin together with thrombomodulin (TM) (endothelial cell surface receptor) activates 
TAFI. Activated TAFI protects the fibrin clot against lysis. PAI blocks the ability for tPA to 
turn on Plasmin, the most important enzyme for fibrinolysis.  
Anticoagulant  
The endothelium is capable of inhibiting the coagulation pathways. Endothelial cells produces 
vasoactive substances and cytokines. Nitric Oxide (NO) and the prostaglandin, Prostacyclin 
(PGI2) both synthesized in the endothelium are powerful vasodilators and efficiently inhibit 
platelet aggregation. Tissue Factor Pathway Inhibitor (TFPI) inhibits the extrinsic pathway by 
blocking the TF: FVIIa complex. Tissue plasminogen activator (tPA) is the major activator of 
the fibrinolytic enzyme plasmin. When thrombin binds to thrombomodulin it can activate 
protein C to active protein C (APC). APC together with protein S and Ca2+ proteolyze FVa and 
FVIIIa and this downregulates thrombin. Finally the endothelium carries Heparan-sulfate 
proteoglycans (HSPG) on its surface. HSPG is a cofactor for Antithrombin III (AT III), the 
main direct inhibitor of Thrombin, FXa, FIXa and FXIa.  
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Figure 3. The Endothelium. The endothelium has pro- and anti-coagulant properties. 
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The Fibrinolytic System16  
Simultaneously as coagulation occurs in response to contact activation or vessel injury the 
fibrinolytic pathway is activated to regulate the thrombogenic response. The fibrinolytic system 
is responsible for degradation of fibrin and solubilization of the formed clot. The injury in the 
vessel needs to be sealed but it is important that a clot does not interrupt the blood stream. 
Plasmin is the central enzyme in the fibrinolysis. Plasminogen is activated by thrombin, Tissue 
plasminogen activator (tPA), FXIa, FXIIa and Kallikrein. Plasminogen is cleaved to plasmin 
which degrades Fibrin to fibrin degradation products. Tissue Factor Pathway Inhibitor (TFPI) 
mediates a endogenous control of TF-driven coagulation. The endothelium is the major source 
of TFPI but TFPI is also stored in platelets and released by thrombin and other agonists. TFPI 
together with Protein C, Protein S and Antithrombin III (AT III) initiates the termination of 
pathological thrombosis. TFPI inhibits TF, FVIIa and FXa. Protein C together with the cofactor 
Protein S inhibits FVa and FVIIIa. ATIII is activated by vessel wall HSPG and is a very 
powerful endogenous anticoagulant that inhibits various proteases such as thrombin, FIXa, 
FXa, FXIa and the TF: FVII complex. tPA converts plasminogen to plasmin, which cuts fibrin 
into soluble fibrin degradation products (FDP). The fibrinolytic pathway is inhibited by 
Plasminogen activator inhibitor (PAI) and Thrombin activatable fibrinolysis inhibitor (TAFI). 
This is necessary to prevent degradation of the important hemostatic plugs (Fig. 4). 
 
 
 
Figure 4. The Fibrinolytic system. Green arrows indicate activation and red arrows inhibition. 
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The TF-FVIIa driven Extrinsic Pathway16 
When a blood vessel gets injured the blood must rapidly clot to form a hemostatic plug to limit 
further blood loss. The Tissue Factor, thromboplastin, pathway of blood clotting is activated 
when plasma gets contact with cells that express the integral trans-membrane protein, TF, on 
the cell surfaces. TF binds with high affinity FVII and FVIIa, a soluble clotting factor. This 
causes an activation of the zymogen FVII to FVIIa. The complex of TF: VIIa adheres on the 
cell surface and is the most potent known activator of the blood-clotting cascade. The formed 
complex triggers clotting in two ways. 1. TF: FVIIa activates FIX via proteolysis. FIXa binds 
with a protein cofactor on a Phospholipid (PL) surface and forms the IXa: VIIIa complex. This 
complex catalyzes the conversion of factor X to FXa. Patients with hemophilia have a 
deficiency in FVIII or FIX.  This makes the blood insufficient to activate FX. 2. TF: VIIa can 
also directly activate FX. Factor Xa together with its cofactor Va on a PL surface catalyzes the 
conversion of prothrombin to thrombin. Thrombin converts fibrinogen to fibrin by proteolysis. 
Fibrin spontaneously forms a gel. Thrombin is also a potent activator of platelets.  
The FXII-driven Plasma Contact Intrinsic Pathway16, 17 
The contact system is activated by coagulation factor XII (Hageman factor) and is active on 
cardiovascular endothelial cells. It is a protease cascade and the plasma proteins trigger pro-
coagulant reactions by the intrinsic pathway and pro-inflammatory reactions by  kallikrein-
kinin. The intrinsic pathway is initiated by FXII in a reaction that involves high molecular 
weight kininogen (HK) and plasma kallikrein (PK). Contact with negative ions induces a 
change of conformation in the zymogen FXII. This results in a small amount of active FXII 
(FXIIa). FXIIa cleaves plasma prekallikrein (PPK) to active PK and this activates more FXII. 
FXIIa initiates fibrin formation via FXI and also releases the inflammatory mediator bradykinin 
(BK) by PK-mediated HK cleavage. BK binds to bradykinin 2 receptors (B2R) and different 
pro-inflammatory signalling pathways that increase vascular permeability, dilate blood vessels 
and initiate chemotaxis of neutrophils and are started. The most important inhibitor of FXII and 
PK is C1 esterase inhibitor (C1INH) (Fig.5). 
 
 
Figure 5. The FXII-Driven Plasma Contact System18. Courtesy of Thomas Renné. 
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Factor XII (FXII, Hagemanfactor) 
Factor XII is a glycoprotein (single-chain) with a half-life in plasma of 50-70 hours. FXII is 
mainly produced in the liver and the gene is located on chromosome 5. FXII binds to 
negatively charged surfaces via a binding pocket in the heavy chain. FXII is activated by 
cleavage of a peptide bond. α-kallikrein (α-PK) is the most potent activator. The product of this 
cleavage is α-FXIIa. Plasmaprekallikrein (PPK) and factor XI are the main targets of α-FXIIa 
during contact activation and α-FXIIa can be cleaved further resulting in β-FXIIa. β-FXIIa 
binds poorly to surfaces and does not support surface-mediated activation of PPK and FXI but 
activates complement factor C1 in plasma. The most important inhibitor of both α- and β-FXIIa 
is C1INH but AT III and PAI also has FXIIa-blocking activity. 
Plasma kallikrein 
Plasma prekallikrein (PPK), Fletcher Factor is the zymogen of α-PK and is primarily expressed 
in hepatocytes but also in pancreatic islets and kidney tubules. The primary mechanism of α-PK 
is to cleave the high molecular weight bradykinin precursor that releases BK. PPK is converted 
by α-FXIIa to active α-PK by a protelytic cleavage. α-PK cleaves HK resulting in released BK. 
In a positive feed back loop α-PK activates surface bound FXII to α-FXIIa. α-PK can also 
convert plasminogen to plasmin. BK initates leukocyte migration, stimulates monocytes, 
induces neutrophil aggregation, chemotaxis and elastase release. 
High Molecular Weight Kininogen 
High Molecular Weight Kininogen (HK) is a glycoprotein predominantly expressed in the 
liver, but also in endothelial cells and α-granules of platelets. HK is cleaved by α-PK, which 
generates Bradykinin. HK undergoes major structural changes upon BK liberation. 
Bradykinin 
Bradykinin is a ligand of the B2-receptor. It is rapidly degraded to inactive peptides by 
angiotensin converting enzyme (ACE) and has a short half-life (< 20 s). BK is a potent local 
inflammatory mediator and regulates local tissue perfusion and increases vascular permeability. 
By initiating an increase in intracellular Ca2+ it activates endothelial NO formation and causes 
vasodilation. BK and other kinins also stimulate the production of PGI2 and PGE2.  
Contact activation 
Contact activation is the mechanism of contact induced FXII zymogen activation. FXII initiates 
fibrin formation but has probably no function for hemostasis in humans. FXII deficient humans 
have no abnormal bleeding tendency despite marked prolongation in aPTT. Deficiency of the 
extrinsic pathway initiator, FVII results in severe bleeding. Complete TF deficiency in mice   
cause intrauterine bleedings and dead fetuses. Humans that lack the other contact proteins, PK 
or HK do not have impaired hemostasis.  Similar to the FXII deficiency. 
FXII can be activated by collagen in the sub-endothelial matrix, polyphosphates, and non-
physiological materials like kaolin, celite, glass or certain polymers. When FXII binds to 
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Polyphosphates it initiates fibrin formation on procoagulant platelets with critical importance 
for thrombus formation. 
The contact system in thrombosis and hemostasis 
Fibrin formation via the intrinsic pathway is triggered by FXII and the contact system. Despite 
initiation of coagulation in vitro, patients that lack FXII have had surgical procedures with no 
bleeding complications. Deficiency of FXII was described the first time 1955 by Ratnoff and 
Colopy19. The patient John Hageman who gave name to FXII was deficient but had no 
increased bleeding tendency. This is in contrast to deficiencies in the extrinsic pathway (FVII, 
TF and FIX) and suggests that fibrin formation in vivo mainly is initiated by the extrinsic 
pathway, with TF: FVIIa. FXII-deficient mice have normal hemostasis but have deficient 
thrombus formation. This indicates that FXII may be crucial for pathologic thrombus formation 
in vivo. FXII gene-deficient mice are spared from the effects of cerebral ischemia in an 
experimental model. FXII-driven fibrin formation is specifically important for fibrin formation 
in thrombosis but has no function for fibrin formation during hemostasis (Fig. 6). 
 
 
Figure 6. Role of FXII in coagulation. Hemostasis: Thrombin (FII) formation at the wound site is mainly due to 
TF exposed in the subendothelial matrix. TF together with FVII initiates thrombin formation leading to fibrin 
formation and platelet activation. FXII-contribution is minor. Thrombosis: When TF Pathway Inhibitor blocks 
FVII activity, additional fibrin forming activity is necessary to form a thrombus. Polyphosphate from platelets 
activates FXII and contributes to thrombin generation, platelet activation and this propagates thrombus growth. 
FXII and FXI deficiency, severely impairs thrombus formation, but do not deteriorate hemostasis20. 
Courtesy of Thomas Renné  
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Thrombosis16 
The word thrombosis originates from the Greek word thrombos, which means a clump or a clot 
of milk. In medicine thrombosis means the presence or formation of a blood clot. Thrombosis 
develops in both veins and arteries, for example deep vein thrombosis or coronary artery 
thrombosis. If the blood clot is detached and travels with the blood stream this is called 
thromboembolism and can be life threatening. This is the case when emboli end in vital organs 
like the lungs (pulmonary embolism (PE)), heart (acute myocardial infarction (AMI)) or brain 
(stroke).  
Venous thromboembolism 
Rudolph Virchow did the first thorough analysis of the pathogenesis of thrombosis. He 
concluded that the consequences of the obstruction could be grouped in three categories. 1. An 
irritation of the vessel and its surrounding. 2. Blood coagulation disturbances. 3. The 
interruption of the blood stream. This combination was later named Virchow’s triad. Known 
risk factors for venous thromboembolism (VTE) includes, increased coagulation factor activity 
(FV Leiden, prothrombin mutation), decreased coagulation inhibitor levels (AT-, Protein C-, 
and Protein S-deficiency), abnormalities in the fibrinolytic system, estrogens, pregnancy, major 
surgery, immobilization, active cancer, long distance travel and central venous lines. Deep Vein 
Thrombosis (DVT: s) most commonly occurs in the lower extremities and the most hazardous 
complication is an embolization to the lungs, pulmonary embolism. Low Molecular Weight 
Heparin (LMWH) is the most common drug both for prophylaxis and the treatment of VTE. 
Arterial Thrombotic Disorders 
Arterial thrombotic disorders are different from VTE. They may originate in atherosclerotic 
plaque (AMI or stroke), in areas of low shear stress like cardio-embolism, in the arterial wall 
after fibro muscular degeneration leading to stenosis or aneurysms and in inflamed arteries 
(Takayasu’s arteritis). Coronary heart disease and stroke are major causes of death in the 
industrialized world. Risk factors include smoking, hyperlipidemia, diabetes, obesity, and 
hypertension. Protective effects have been found in regularly intake of fruit and vegetables, 
exercise and small amounts of alcohol. Treatment of arterial thrombotic disorders varies a lot. 
Fibrinolytic therapy with recombinant tPA or percutaneous coronary intervention (PCI), a 
balloon-catheter that is inflated to open a closed coronary artery is two examples in AMI. 
Surgical embolectomies and bypass procedures or stents placed in blood vessels with 
angiographic guidance are other examples in peripheral arterial disease.  
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Therapeutic Agents targeting the Hemostatic System 
Anticoagulants 
Anticoagulants are drugs that prevent coagulation and clotting. 
Citrate 
47% of the body’s Ca2+ is free in solution as ionized iCa2+, which is the physiologically active 
form. iCa2+ is necessary for hemostasis as a cofactor for phospholipid dependent assembly of 
many coagulation factors 21, 22. Citrate chelates calcium and prevents activation of both platelets 
and the coagulation cascade. Citrate has been the standard anticoagulant for blood transfusions 
and stored blood products for many years.      
Heparin (UNFH) 
Unfractionated Heparin (UNFH) is a glycosaminoglycan that binds to the enzyme inhibitor 
Antithrombin III (AT III) and increases the effect of AT III up to 1000 times.  AT III 
effectively inhibits thrombin and FXa but also IXa, Xa and XIIa. Both the intrinsic and 
common pathways of coagulation are inhibited. Heparin is used as treatment of DVT, PE, as 
prevention for post-surgery thrombosis and to prevent clotting in ECMO-circuits, during 
cardiopulmonary bypass and hemodialysis23.  
Low Molecular Weight Heparin (LMWH) 
Low Molecular weight Heparin (LMWH) is fractionated heparin with shorter molecule chains 
that causes exclusive indirect FXa inhibition. Examples are Dalteparin (Fragmin®) Tinzaparin 
(Innohep®) and Enoxaparin (Klexane®)24. 
Direct inhibitors of FXa 
Direct inhibitors of FXa are oral anticoagulants that inhibit both the common pathway of 
coagulation. There is no antidote is available for these drugs. They are used as prevention of 
embolism in atrial flutter (AF), DVT, PE and after surgery. Two examples of direct inhibitors 
of FXa are Rivaroxaban (Xarelto®) and Apixaban (Eliquis®)25. 
Indirect inhibitors of FXa 
An indirect inhibitor of FXa is synthetic pentasaccharide, which is chemically related to 
LMWH. It targets FXa rather than ATIII and inhibits FXa but not Thrombin. Fondaparinux 
(Arixtra®)26 is one example. 
Vitamin K antagonists (VKA) 
Vitamin K antagonists (VKA) blocks the liver enzyme Vitamin K epoxireductase, that prevents 
vitamin K to add carboxyl groups on FII, VII, IX and X. Therefore it inhibits both the extrinsic 
and common pathways of coagulation. The most used VKA is the coumarin derivative 
Warfarin (Coumadin®, Waran®)27.  
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Direct inhibitors of Thrombin (DTI) 
There are two types of direct inhibitors of thrombin (DTI). Univalent DTIs bind to thrombin’s 
active site, e.g. Dabigatran (Pradaxa®). Bivalent DTIs binds both to the active site and exosite1. 
and have a transient inhibition profile, e.g. Bivalirudin (Angiomax®). The anticoagulant effect 
of DTIs cannot be reversed 25.  
Antithrombin III Concentrate (AT III) 
Antithrombin III is used preoperatively to treat Heparin resistance or for VTE in primary or 
acquired AT III deficiency (Thrombate®) 28. 
 
Platelet aggregation inhibitors 
Platelet aggregation inhibitors are drugs that blocks platelet aggregation, activation or their 
adherence to the vessel walls. 
Acetyl salicylic acid (ASA) 
Acetyl salicylic acid inhibits the endothelium’s prostaglandin synthesis by irreversible 
inhibition of cyclooxygenase. Reduced prostaglandin levels prevent platelets to aggregate. 
Aspirin® and Trombyl® are two examples29 of ASA. 
Clopidogrel 
Clopidogrel causes an irreversible inhibition of the ADP receptor P2Y12 on platelet membranes 
and thereby inhibits aggregation of platelets30. Plavix® is a well-used drug containing 
clopidogrel. 
Ticagrelor 
Ticagrelor is an antagonist of the P2Y12 receptor30 that inhibits the platelet aggregation (e.g. 
Brilique®). 
Prostacyclin (PGI2) 
Prostacyclin (PGI2) inhibits platelet activation and platelet adherence to the vessel walls. PGI2 
also acts as a vasodilator, e.g. epoprostenol31 (Flolan®). 
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Thrombolytics 32  
Clears and breakdowns fibrin clots. Used as a thrombolytic agent for massive DVT, PE, and 
AMI or to degrade occlusions in intravenous and dialysis catheters. 
Recombinant tPA 
Recombinant tPA catalyses the cleavage of plasminogen to plasmin, together with fibrin. It has 
a high affinity for plasminogen bound fibrin and breaks down the fibrin. Alteplas (Actilyse®) is 
a well-documented drug containing tPA. 
Urokinase 
Urokinase plasminogen activator (uPA) catalyses the conversion of plasminogen to plasmin 
and is used as thrombolysis in PE and AMI, e.g. Abbokinase®. 
Streptokinase 
Streptokinase is an effective and inexpensive fibrinolytic used as treatment in AMI and PE. 
Streptokinase is also secreted by streptococci and it activates plasminogen, e.g. Streptase®. 
 
Procoagulants 
Substitutes coagulation factors, inhibits fibrinolysis, stimulates platelets or are antidotes to 
anticoagulants. 
Antifibrinolytics 
The most well known antifibrinolytic is tranexamic acid and it prevents fibrinolysis by 
competitively inhibiting the activation of plasminogen to plasmin33, e.g. Cyklokapron®. 
Prothrombin complex concentrate (PCC) 
Prothrombin complex concentrate is a plasma product containing vitamin K dependent 
proteins; FII, VII, IX and X. PCC treats bleeding due to deficiency of Vitamin K coagulation 
factors or reverse the effect of Warfarin 34, e.g. Confidex® and Beriplex®. 
Vitamin K 
Vitamin K is used as treatment for bleedings caused by low prothrombin complex (F II, VII, IX 
and X). It is also an antidote to VKA: s 35. Vitamin K1 is Fytomenadion, which is distributed as  
Konakion ®.  
Desmopressin Acetate 
Desmopressin Acetate releases FVIII and vWF from the endothelium, which stimulates the 
platelets to aggregate and shortens the bleeding time36 (e.g. Octostim®, DDAVP®). 
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Recombinant FVIIa (rFVIIa) 
Recombinant FVIIa is a very important drug for the treatment of FVII deficiency and 
Hemophilia.  rFVIIa has also been used in trauma with conflicting results.37, 38, e.g. 
NovoSeven®RT. 
Protamine 
Protamine is an effective antidote to UNFH and LMWH. It works by electrostatic binding to 
these molecules and block their anticoagulant effect. Protamine is commonly used as reversal 
of UNFH at the end of heart surgery39, e.g. Protaminsulfat® Leo Pharma. 
Fibrinogen 
Fibrinogen is used for congenital fibrinogen deficiency and for fibrinogen consumption during 
for example ECMO40, e.g. RiaSTAP®. 
Recombinant FXIII (rFXIII) 
Recombinant FXIII is used for treatment of congenital factor XIII deficiency41, e.g. 
Fibrogammin P®. 
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Measuring coagulation and anticoagulation 
Activated Partial Thromboplastin Time (aPTT)42 
The Activated Partial Thromboplastin Time (aPTT) measures the activity of the intrinsic and 
common pathways of coagulation and is used for preoperative screening and monitoring of 
anticoagulative therapy. aPTT is sensitive to plasma levels of the contact factors XII, XI and 
FV, VIII, IX, X, prothrombin and fibrinogen. The term ”partial” indicates that phospholipid is 
included but not Tissue Factor, which is necessary for activation of the extrinsic system.  The 
term ”thromboplastin” means the complex of the clotting factors that convert pro-thrombin to 
thrombin and the final synthesis of fibrin. Citrated platelet poor plasma (PPP) is warmed to 
37°C. Phospholipid and a contact activator, e.g. kaolin, is added followed by calcium. The 
addition of calcium initiates the clotting and aPTT is the time from the addition of calcium to 
the formation of fibrin. 
Reference value: 30-50 s 
Activated Clotting Time (ACT)43 
Activated Clotting Time was first described by Hattersley in 196644. It is a bedside or point of 
care test (POCT) of coagulation used to monitor the anticoagulant effect of UNFH in patients 
on bypass surgery, on ECMO, hemofiltration or hemodialysis. Fresh, whole blood is added to 
a tube containing a surface activator, such as kaolin or a glass. This results in the activation of 
coagulation by the contact pathway.  
Reference value: 107 ± 13 s 
Therapeutic range in CPB and heart surgery: 400-600 s 
Therapeutic range in ECMO: 220-260 s 
Anti-FXa45 
Anti-FXa is a test that measures the activity of heparin. Plasma is added to a reagent with 
factor Xa. Heparin from the patient binds AT III and inhibits FXa. The amount of Heparin in 
the patient’s plasma is inversely proportional to the amount of remaining FXa. This can be  
used to calculate the anti-FXa level. Anti-FXa is useful in patients with heparin resistence or 
with an underlying condition that interferes with the aPTT test.  
Therapeutic ranges:  LMWH: 0.5-1.2 IU/mL UNFH: 0.3-0.7 IU/mL 
Profylactic ranges:  LMWH: 0.2-0.5 IU/mL UNFH: 0.1-0.4 IU/mL 
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Antithrombin III (AT III) 46 
Antithrombin III is a test performed to test if patients are responding as expected to Heparin or 
if they are AT III deficient. In some patients with AT III deficiency, AT III needs to be given to 
reach a normal anticoagulant effect of heparin. 
Reference value: Newborn: 60-90% Children and Adults: 80-120% 
Plasma concentration: 0.15-0.2 mg/mL 
Bleeding Time47 
The skin bleeding time is a measure of global hemostatic competence in vivo. A standardized 
incision is made in the subjects forearm (Surgicut® or Simplate® II). The specificity and 
sensitivity for Skin Bleeding Time (SBT) in von Willebrand Disease (vWD) is low as well as a 
predictor of surgical bleedings. It is seldom used clinically nowadays. 
Reference value: 2-10 min. 
Platelet Count (TPK)48 
The Platelet Count, or in Sweden Trombocyt Partikel Koncentration (TPK), is an assay that 
detect the amount of platelets in the blood. Acceptable level for normal hemostasis is 
considered to be 50 x 109/L. 
Reference value: 150-450 x 109/L 
Prothrombine Time (PT)49.  
The Prothrombine Time (PT) measures the activity of the tissue factor pathway of coagulation 
and is used as preoperative screening, measuring of warfarin effect, liver dysfunction and 
vitamin K status. PT is sensitive to plasma levels of FVII, X, V, prothrombin and fibrinogen.  
Citrated PPP is incubated at 37°, Ca2+ in a phospholipid suspension is added to normalize the 
blood clotting ability and finally TF is added. The time is controlled from the addition of TF to 
the formation of fibrin. 
Reference value: 12-13 s 
International Normalized Ratio (INR)50 (PTtest/PTnormal)ISI 
According to which test of PT is being used, different batches of manufacturers TF can vary.  
To overcome these differences the manufacturers assigns an International Sensitivity Index 
(ISI) value (ranging from 1-2). The INR is the ratio of a patient’s prothrombine time to a 
control sample (normal) raised to the power of the ISI value for the used analytical system. 
Reference value:  0.8-1.2 Therapeutic Interval: 2.0-3.5 
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Thromboelastography and Rotational Thromboelastometry (ROTEM®*)51 
Tromboelastography (TEG) was developed by Prof. H. Hartert in Heidelberg during WWII52. 
In the 1980’s the interest in TEG increased in USA for management of acute bleeding patients 
and in 1993 TEG became a trademark for an American Company. The ROTEM®   system is an 
enhancement of TEG and was developed 1995-1997 in Germany. It includes an electronic 
pipette, four measurements channels and an integrated computer for automatic analysis. The 
citrated blood sample is in a cuvette where a cylindrical pin rotates. When the blood clots it 
limits the rotation of the pin more and more with rising clot firmness. This is detected optically 
and the computer calculates the ROTEM® curve and its numerical parameters. The curve is 
plotted two-sided and expressed in mm and time is calculated in seconds.  
Definition of ROTEM measurements 
EXTEM 
EXTEM examines the Extrinsic -Tissue Factor induced coagulation. 
INTEM 
INTEM examines the Intrinsic- Contact induced coagulation.  
FIBTEM 
In FIBTEM cytochalasin D blocks the platelets and only Fibrins contribution is analyzed. 
CT (Clotting Time) 
Clotting Time is the time from start until initiation of clotting. The thrombin formation time (s). 
CFT (Clot Formation Time) 
Clot formation time is the time when a clot size of 20 mm is detected. It measures both fibrin 
synthesis and reinforcement with platelets and FXIII (s).  
MCF (Maximum Clot Firmness) 
The maximum clot firmness measures the stabilization by fibrin, platelets and FXIII (mm). 
ML (Maximum Lysis) 
The maximum lysis is a measure of the reduction of firmness after MCF. ML <15% at 1 hour 
indicates a stable clot and ML >15% at 1 h indicates pathologic fibrinolysis. 
 
*(ROTEM® is a registered trademark of Tem innovations GmbH, Munich, Germany) 
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Flow Chamber System53-55   
 
A flow chamber is a device used to investigate in vitro thrombus formation under flow. By 
adjusting the flow rate (ml/h), the shear rate (s-1) can be varied to simulate venous or arterial 
flow conditions. On the flow chamber a coated cover slip is placed containing thrombogenic 
material. The most common coating material is collagen but also vWF, fibrinogen, 
fibronectin as well as endothelial cells and atherosclerotic plaque material can be used. To 
avoid clotting the blood is collected into Ca2+/Mg2+-chelating anticoagulants such as citrate or 
ethylenediaminetetraacetic acid (EDTA). As the function of many plasma coagulation factors 
is Ca2+-dependent the blood needs to be recalcified before entering the chamber to provide 
free ions for induction of thrombus formation. The thrombus formation is followed in real-
time using a digital camera coupled to a microscope. 
It is possible to measure platelet adhesion, aggregation and coagulation but also to determine 
the roles of platelet receptors and signaling proteins. Flow chambers are also excellent tools 
to analyze the intrinsic pathway of coagulation56.  
The flow chamber used in this thesis consists of a transparent polycarbonate block with an 
engraved rectangular area (width 5 mm, height 50 µm). Inlet and outlet tubes are drilled at an 
angle of 20° to avoid flow disturbances.  
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Hypovolemic Shock in Trauma57 
Definition 
Shock is defined as an abnormality for the circulatory system that results in inadequate organ 
perfusion and tissue oxygenation. Shock can have different causes, hypovolemia, heart failure, 
CNS-injury or sepsis. In trauma, the by far most common cause of shock is hypovolemia and is 
in focus in this presentation. Causes of hypovolemic shock in trauma are injuries to blood 
vessels (arteries or large veins), highly circulated organs (the heart, lungs, liver, spleen or 
kidneys) and fractures of femur and pelvis. A ruptured ectopic pregnancy and burns can also 
result in hypovolemic shock. Cardiac Output (CO) is the volume of blood pumped by the heart 
per minute (L/min). CO is determined by multiplying the HR (beats per min) and the stroke 
volume (ml/beat). The stroke volume (amount of blood pumped with each cardiac contraction) 
is determined by, preload, myocardial contractility and afterload. Preload is mainly a result of 
the blood volume on the venous side. Normally approximately 70% of the body’s blood 
volume is on the venous side and a major loss of the blood volume decreases preload and may 
cause a hypovolemic shock. Myocardial contraction drives the circulatory system and 
Afterload is the resistance to the forward flow of blood out of the pulmonary arteries or the 
aorta. 
Pathophysiology 
Blood loss results in vasoconstriction and a decrease in visceral, cutaneous and muscle 
circulation. This response preserve blood supply to more vital organs like the kidneys, heart 
and brain. Endogenous catecholamine increases the peripheral resistance, which increases the 
diastolic blood pressure (DBP) and decrease the pulse pressure (PP). Breathing is affected with 
increased respiratory rate (RR) and with diminishing blood volumes urinary output (UO) 
decreases and the mental status is affected. Histamine, Bradykinin, β-endorphins and 
prostanoids (prostaglandins, prostacyklins and Thromboxanes (TXA2) are other vasoactive 
hormones that are released into the circulation during shock. The earliest signs of bleeding are 
tachycardia and peripheral vasoconstriction resulting in, cool, whitened skin and extended 
transcapillary refill (TCR) > 2s. Low oxygenation of the peripheral organs induces anaerobic 
cell metabolism, which results in formation of lactic acid and metabolic acidosis. Prolonged 
shock with inadequate delivery of ATP destroys the cell membrane integrity and normal 
electrical gradient. Swelling of the endoplasmic reticulum, mitochondrial damage, lysosome 
rupture with release of cytotoxic substances soon follows. Sodium and water enters the cell and 
swelling starts. During hypovolemic shock Ca2+ gets deposited inside cells. 
Hemorrhage means an acute loss of circulating blood volume. The blood volume of an adult is 
approximately 7% of the body weight (e.g. 70 kg ≈ 5L) and for a child 80 ml/kg. Hemorrhage 
is divided in four different classes. The following estimated blood losses are for a 70 kg male. 
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Class I-IV Hemorrhage 
 
Class I Hemorrhage 
In Class I Hemorrhage, up to 15% (750 mL) of the blood volume is lost. This results in 
minimal tachycardia, no change in blood pressure, pulse pressure, respiratory rate or urinary 
output. The patient gets slightly anxious.  
Class II Hemorrhage 
In Class II Hemorrhage, 15-30% (750-1500 mL) of the blood volume is lost. Tachycardia (HR 
100-120) and tachypnea (RR 20-30) is present. The systolic blood pressure is normal but 
diastolic pressure is increased and the pulse pressure gets decreased. Urinary output is reduced 
to 20-30 ml/h. The patient is anxious, hostile or frightened.  
Class III Hemorrhage 
In Class III Hemorrhage, 30-40% (1500-2000 mL) of the blood volume is lost. Marked 
tachycardia and tachypnea (HR120-140, RR 30-40) is present. There is a clear drop in systolic 
pressure and decreased pulse pressure. The urinary output is 5-15 ml/h and the patient can be 
confused. Class III hemorrhage requires blood transfusion and if necessary emergency surgery. 
Class IV Hemorrhage 
In Class IV Hemorrhage, > 40% (> 2000 mL) of the blood volume is lost. This is an 
immediately life-threatening situation. Marked tachycardia (HR >140) to bradycardia is noted. 
There is a significant decrease in the systolic blood pressure and a very narrow pulse pressure. 
The diastolic blood pressure may be impossible to measure. The skin is cold and pale and the 
urinary output is negligible. The patient is confused or lethargic. Class IV Hemorrhage requires 
rapid blood transfusion and immediate surgical intervention. 
It must be remembered that the classification above is somewhat arbitrary. Trauma patients in 
bleeding shock can have both normal cardiovascular and respiratory status. There is no single 
factor (metabolic or physiological) that identifies all patients in hemorrhagic shock. 
Treatment of hemorrhagic shock 
The treatment is directed to reverse the shock state by providing adequate oxygenation and 
appropriate fluid/blood resuscitation. Control of hemorrhage and restoration of adequate 
circulating volume is essential. Vasopressors are contraindicated because they worsen the tissue 
perfusion. See Damage Control Resuscitation and Damage Control Surgery below. 
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Trauma Induced Coagulopathy  
Definitions 
It is well known that severe trauma with hemorrhage induces coagulopathy. This is a state 
when the blood’s ability to coagulate (form clots) is impaired. Massive blood transfusion 
(MBT) is required in 15% of multi-trauma patients but is inevitably followed by hypothermia 
and acidosis. This exacerbates the coagulopathy. The risk of dying is highly increased in 
coagulopathic patients58 and patients receiving MBT59. Hypothermia (body 
temperature < 33 °C) and metabolic acidosis (pH<7.2) increases the mortality rate to 90%60-62. 
Trauma Induced Coagulopathy (TIC) is a complex process. It is only in the last years that the 
pathophysiology of TIC has started to be known and it seems to be the result of an imbalance of 
platelets, pro-coagulation, anti-coagulation, endothelium and fibrinolysis63. Acute Traumatic 
Coagulopathy (ATC) is a definition of the endogenous part of TIC. In clinical and laboratory 
studies, tissue injury alone does not lead to coagulopathy64. Tissue injury needs to be combined 
with hypoperfusion of organs to induce ATC65. ATC is probably a combination of factor V 
inhibition, low fibrinogen, anticoagulation, impaired platelet function and hyperfibrinolysis. 
ATC is aggravated by acidosis, hypothermia and hypo-coagulable fluids. This causes 
established TIC66. In the following text known factors of ATC will be discussed. 
1) Definition of TIC: INR>1.2, aPTT> 40s, Platelets<120, ROTEM amplitude<35 mm at 5 min64, 67. 
Procoagulant impairment 
Factor V 
ATC develops rapidly after trauma with bleeding shock. A study of 45 trauma patients were 
coagulation was controlled at the scene, before fluid infusion and on hospital admission showed 
that 56% had abnormal coagulation 25 min after trauma68. In another recent study coagulation 
factors from 110 adult trauma patients with ISS > 15 were controlled. FII, V, VII, VIII, IX, X, 
XI and XII were analyzed. 22 of the patients had a critical coagulation factor deficiency (< 
30%) but there were no total consumption of coagulation factors. All of the 22 cases had a 
deficiency of Factor V. Five patients had a critical deficiency in other factors 69. FV is a central 
coenzyme that together with Ca2+ helps FXa to convert pro-thrombin to thrombin. Activated 
Protein C (APC) causes FV inhibition. A conclusion of this study was that APC might have 
caused an isolated deficit of factor V.  
Fibrinogen 
Fibrinogen declines rapidly after trauma. A prospective randomized study with 80 trauma 
victims compared coagulopathic and non-coagulopathic patients. It showed a significantly 
lower fibrinogen levels in patients with ATC (1.53 vs. 2.54 g/L, p<0.001)70. Fibrinogen is the 
central substrate for fibrin strands that reinforce platelet-clots and low fibrinogen level is an a 
predictor of mortality at both 24 h and 28 days (p<0.001)71. 
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Systemic anticoagulation and hyperfibrinolysis 
Protein C 
ATC may be mediated by Protein C. A prospective observational study of 203 major trauma 
patients showed that combined severe traumatic injury and hypoperfusion activated the protein 
C pathway with coagulopathy as result. APC was significantly increased, factors V and VIII 
inactivated and fibrinolysis increased. Elevated APC-levels were associated with increased 
blood transfusion requirements, organ injury and mortality72. Another component of ATC is 
hyperfibrinolysis. The mortality rate in trauma patients with fulminant hyperfibrinolysis 
exceeds 80%73. Tranexamic acid is an antifibrinolytic drug that competitively inhibits the 
activation of plasminogen to plasmin. In a RCT in trauma patients the effects of tranexamic 
acid on death, blood transfusion and thrombotic events were analyzed74. More than 20000 
patients in 274 hospitals were included and tranexamic acid made a safe reduction on the risk 
of death and is now recommended as a standard treatment for bleeding trauma patients. 
Platelet dysfunction  
Platelet (PLT) count is reduced in trauma and the odds of death at 24 hours in massively 
transfused trauma patients was shown to decrease 12% for every 50x109/L increase in platelet 
count75. A high ratio of PLT to Packed Red Blood Cells (PRBC: s) improves outcome76. Other 
studies show conflicting results and it is not clear what is most important, the number or 
platelets or the impaired platelet function of the platelets. Further studies are needed. 
Endothelial activation 
The Endothelium contributes to ATC. Thrombomodulin and protein C receptors are anchored 
to the capillary beds and capture thrombin thus accelerating protein C activity. APC inactivates 
FVa and FVIIIa but also consumes PAI, the major inhibitor of tPA. Traumatic hemorrhage and 
hypoperfusion leads to a vast release of tPA from the endothelium and this results in 
hyperfibrinolysis65. Another known anticoagulant event during trauma, apart from activation of 
PC, is auto heparinization, which is linked to endothelial glycocalyx degradation77. This 
degradation triggers for thrombin formation, protein C activation and hyperfibrinolysis. 
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Acidosis, Hypothermia, Hypocalcemia and Hemodilution 
Hemorrhage, exposure to low temperature, hypoperfusion and hypocoagulable fluids causes 
acidosis and hypothermia. For coagulopathy to develop the pH needs to be below 7.2 and the 
body temperature less than 33°C 78. Hypothermia, 33-37°C, impairs platelet function and the 
formation of a platelet plug. Below 33°C, the enzyme activity is also strongly reduced, which 
contributes to coagulopathy79. Calcium is a necessary cofactor for the activation of several 
coagulation factors. Hypocalcemia is mainly the result of transfusion with citrated blood 
products, especially fresh frozen plasma (FFP). The faster the transfusion the faster the 
reduction in Calcium. S-Ca2+ < 0.9 mmol/L shall be treated80. High volumes of crystalloid or 
colloid fluid administered to trauma victims are associated with worsened coagulopathy, 
increased requisite of blood products and an increased risk of MOF. To minimize the risk of 
iatrogenic induced coagulopathy, damage control resuscitation (DCR) is recommended 64, 81. 
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Contemporary Trauma Surgery 
Advanced Trauma Life Support13 
Advanced Trauma Life Support (ATLS) is a concept of triaging trauma victims that was 
initiated after a tragic plane crush involving an orthopedic surgeon and his family in Nebraska 
1976. The surgeon meant that he could provide better care to himself and three of his seriously 
injured children than the care they received at the primary care facility. He saw a need for a 
new trauma system and ATLS was developed. The concept has been spread around the world 
and today more than 50 countries use it to train doctors involved in trauma care. In ATLS 
injuries are prioritized and handled according to ABCDE. A means Airway with C-Spine 
protection, B means Breathing, C means Circulation, D is Disability and E stands for Exposure 
of the entire body. ATLS-courses provide lifesaving knowledge for the initial treatment of 
injured patients but do not teach definitive care.  
Damage Control Surgery14 
Historically Navies used the term Damage Control as the emergency control of situations that 
might have caused the sinking of a ship. The term Damage Control Surgery (DCS) was 
popularized in trauma by Michel Rotondo in the 1990s82 and refers to the rapid termination of 
an operation, after control of life-threatening bleedings and contamination, in favor of 
correcting the physiology in the ICU. Definitive treatment is delayed until the patient is stable 
and may be postponed for hours-days. One important goal is to correct the lethal triad of 
hypothermia, acidosis and coagulopathy. Examples of acute lifesaving DCS procedures are 
acute amputation of bleeding extremities, external stabilization of pelvic fractures, Pringles 
maneuver83 or perihepatic packing of liver-injuries84, drainage of bile leakage, stapling and 
resection of injured bowel, acute splenectomy, shunting of the blood stream in injured blood-
vessels, but also angiographic guided embolization of bleeding vessels. DCS has become the 
standard of treatment for severely injured patients worldwide85 and in the year of 2000 more 
than 1000 patients had been treated with this concept86. 
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Damage Control Resuscitation 
In earlier ATLS manuals high volumes of crystalloids were recommended but during recent 
years it has become obvious that a restriction of i.v. fluids improve the care of lethally injured 
patients. This led to the concept Damage Control Resuscitation (DCR) and permissive 
hypotension. Since DCR was introduced there has been a fall in trauma related mortality87. The 
concept of permissive hypotension is transfusion of blood products to increase the blood 
pressure, not aiming for normotension but for a more cerebral alert patient. The goal is to keep 
SBP in penetrating trauma at 70-80 mm Hg, and SBP in blunt trauma at 90 mm Hg.  The time 
of hypotension needs to be kept at a minimized with immediate transfer to the operating room.  
Damage Control Resuscitation 88 
1. Permissive hypotension  and hypovolemia. The systolic blood pressure should be kept at 80 
mm Hg (90 mm Hg in associated brain injury). 
2. Hemostatic transfusion (resuscitation) with FFP, PRBC, Platelets and Tranexamic Acid 
Avoidance of crystalloids and vasopressors. 
3. DCS or Angiography to treat the hemorrhage. 
4. Restoration of organ perfusion and oxygen delivery. 
DCR is indicated in patients with hemorrhage class III and IV and a transfusion speed of more 
than 4 units of PRBC: s in the initial 2-4 hours.  
 
Definitive Surgical Trauma Care15 
In 1993 five surgeons and members of the International Society of Surgery (ISS) and the 
International Association for Trauma Surgery and Intensive Care (IATSIC) met in San 
Fransisco at the meeting for American College of Surgeons (ACS). They had realized that there 
was a specific need for surgical training in trauma. It was believed that a short course focusing 
on life-saving techniques and surgical decision-making was required for surgeons, who dealt 
with major trauma on an infrequent basis. The course would meet a worldwide need that 
supplemented the ATLS-course. A curriculum and manual that forms the basis of the Definitive 
Surgical Trauma Care™ (DSTC) was approved in 1999 and the first manual was published in 
2003. Since then the course has been delivered in more than 24 countries. In the DSTC course 
the following topics are covered. Physiology and the metabolic response to trauma, transfusion 
in trauma, DCS and the abdominal compartment syndrome, surgical decision making in major 
trauma and organ-orientated surgical techniques in trauma 89.  
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Extracorporeal Membrane Oxygenation90 
History of ECMO 
Extracorporeal Membrane Oxygenation (ECMO) literary means the oxygenation of blood on a 
membrane outside the body. ECMO can also be regarded as a modified heart-lung machine. 
The first known blood transfusions, between humans and lamb, were done by Richard Lower in 
Three hundred years later in 1953 the first heart surgery on cardiopulmonary bypass (CPB), an 
atrial septal defect, was performed by Dr. John Gibbon. In 1960 the first membrane 
oxygenators were introduced and during the years to come oxygenators and other devices were 
continuously improved. Silicone membrane oxygenators reduced the risk of hemolysis and the 
use of them led to the term ECMO. The first ECMO was performed 1971 when Dr. JD Hill 
cannulated a motorbike victim with post-traumatic ARDS 91. During this period Dr. Robert 
Bartlett, the father of modern extracorporeal support, was collaborating with engineering 
researchers. Bartlett was the first to use ECMO in children and neonates92. In 1975 a baby girl 
was born with meconium aspiration syndrome (MAS). Her mother was a refugee from Mexico 
and had abandoned her baby at the Californian border. Conventional intensive care treatment 
failed. Dr. Bartlett and his team treated her with ECMO for 72 hours. The little girl survived 
and the staff named her Esperanza, which is Spanish for “hope”. ECMO was brought to 
Stockholm in 1987 by collegues Ds. Frenckner and Palmér and the first patient was a baby boy 
with Congenital Diafragmatic Hernia (CDH). He survived and in September 2015 ECMO 
Center Karolinska had treated more than 1000 patients. ECMO is spreading around the world 
and centers are being established continuously. To date more than 69000 patients have been 
treated worldwide and there are more than 200 centers reporting to the ELSO registry90. 
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ECMO physiology 
Systemic Oxygen delivery (DO2) is the amount of oxygen delivered throughout the body each 
minute and the product of Cardiac Output (CO) and the arterial oxygenation. At rest DO2 is 5 
times greater than the consumption (VO2) and in healthy subjects there is a cardiorespiratory 
homeostasis. When VO2 changes, DO2 changes as well. If cardiac output is decreased the 
oxygen increases, which will result in a decreased venous saturation.  DO2 is controlled by CO, 
Hemoglobin (Hb) amount, Hb saturation and dissolved oxygen.  Oxygen is present in blood; 
both dissolved in plasma and bound to red blood cells by hemoglobin. Hemoglobin bound O2 is 
critical for the oxygen transport because the amount of free dissolved O2 negligible in plasma. 
Each gram Hb can bind 1.34 ml O2. The oxygen consumption can be calculated as the arterial-
venous oxygen content difference time cardiac output. Red cells pass one at a time in the lung 
capillaries leaving CO2 and binding O2 through passive diffusion and the amount of oxygen 
absorbed is exactly equal to what is consumed in the metabolism. CO2 is excreted in the alveoli 
of the lung and is normally maintained at PCO2 40 mm Hg.  The Cardiac Output is the result of 
preload, the heart rate, cardiac contraction, and the resistance in the arteries. The blood volume, 
vascular tone and blood viscosity (hematocrit) all regulate these factors. Hypovolemia 
(hemorrhage) results in a cathecolamine mediated increased HR, raised contraction and 
vasoconstriction. Heart failure can be treated with assistance of these reflexes by increasing 
blood volume (transfusion), vasoactive drugs (e.g. norepinephrine and dopamine) or 
mechanical support (ECMO). When DO2 is severely decreased (DO2/VO2 < 2:1) the metabolic 
demands are greater than the delivered oxygen and anaerobic metabolism leads to acidosis. The 
venous saturation in the Pulmonary Artery (PA) reflects the DO2/VO2 ratio and is an important 
parameter for monitoring the ICU patients. If the oxygen extraction is 30% the venous 
saturation is 70% for example. In sepsis the VO2 is higher than normal and forces the DO2 to 
rise, to maintain the 5:1 ratio. ECMO can be used either as a pure lung support, veno-venous 
(VV ECMO) or if it bypasses the heart as veno-arterial (VA ECMO), meaning a full support of 
the heart and lungs. In the latter setting the patient’s central circulation is maintained even if the 
native heart arrests. The ECMO Circuit consists of cannulas for drainage and infusion of blood, 
surface heparinized tubings, a roller- or centrifugal pump, a heater and the membrane-
oxygenator (Fig. 7) Both in VV and VA ECMO blood is drained from the venous side, either 
from the right atrium of the heart or the inferior vena cava or both. Carbon dioxide is removed 
and oxygen is added through the membrane artificial lung. In VV ECMO, blood reenters the 
vascular system on the venous side of the heart, whereas in VA it enters in a major artery. In 
VA ECMO the total systemic blood flow is the sum of extracorporeal flow and the blood flow 
from the heart which means that the O2-and CO2 content depends on how much each factor 
contributes. In VV ECMO the perfused blood is returned on the venous side and mixed in the 
right atrium, increasing the O2- and reducing the CO2 level. Some of the venous blood will re-
enter the ECMO system (referred to as recirculation) but the major part passes through the heart 
and lungs. If the lungs have active parts the saturation will increase further and the systemic 
circulation depends totally on the native heart function. Generally, indication for VV ECMO is 
resistant hypoxemia despite optimized ventilator management. VA ECMO is indicated when 
the former indication is combined with a persisting heart failure despite conventional treatment 
and vasopressor support. 
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ECMO illustration 
 
 
 
 
 
 
 
 
Figure 7. ECMO-circuit (veno-venous). Draining dual lumen cannula in the right atrium, venous blood (blue) 
is drained to a centrifugal pump, oxygenation and warming of the blood performed in the membrane 
oxygenator, oxygenated blood (red) is reinfused in the right atrium. Pressures are measured before the pump 
(P1), before the oxygenator (P2) and before the patient (P3). The blood flow is controlled with a flowmeter. 
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ECMO in trauma 
In 1971 Dr. J Hill was the first physician who used prolonged extracorporeal treatment outside 
of the operating room. The patient was a 24-year-old motorcyclist who had sustained a ruptured 
aorta and a post-traumatic acute respiratory distress syndrome (ARDS). The patient received 
venoarterial support for 75-hours and survived91. 5 years later Mattox reported of 39 patients 
whose critical condition prevented them to be transported to the operating room. Ten of the 
patients had massive traumatic thoracic injuries. They were supported with a portable 
cardiopulmonary bypass and in eight of the patients the hemorrhage could surgically be 
controlled, and the bypass discontinued93. After this the literature concerning ECMO and 
trauma was sparse for almost twenty years. There are three major reasons imaginable for this.  
Firstly, the ECMO systems have been considered to be to complicated, time consuming and 
difficult to connect to the patient. Secondly, extracorporeal oxygenation has traditionally been 
associated with systemic heparin, which obviously is contraindicated in the traumatized patient. 
Thirdly, few centers have had a team on 24h-7d stand by for emergency cannulations. In 1995 
Perchinsky et al reported on six massively injured patients who received ECMO without 
systemic heparin. Three of the patients survived and they concluded that ECMO with heparin-
bonded circuits could offer safe support while the primary injuries were being evaluated and 
treated94. From the end of the 1990s and forward reports on ECMO after trauma has been 
more frequent. Michaels et al reported, in 1999, of 30 patients were ECMO was safely used 
in trauma patients with multiple injuries and severe pulmonary failure. Early implementation 
of ECMO was associated with improved survival95. The positive effects of ECMO in 
posttraumatic ARDS have been verified in additional reports and can no longer be regarded 
as controversial96-100. The use of ECMO in trauma with hemorrhagic shock is uncommon and 
somewhat controversial. 
In 2010 Dr. Matthias Arlt and his group in Regensburg were the first to report on a series of 
ECMO treated adult trauma patients with bleeding shock101. Their results have initiated a new 
way of thinking. The application of the extracorporeal circuit, not only for gas exchange, but 
also as heart and lung support in a critical state with hemmorhagic shock and coagulopathy 
opens for new, unknown effects and indications. Dr. Arlt and his group treated ten severely 
injured trauma patients, with a mean ISS of over 70. Seven received VV ECMO and three 
VA ECMO. Cardiopulmonary failure was effectively stabilized. Systemic gas exchange and 
blood flow was rapidly improved within 2 h on ECMO. The bypass was combined with a 
specially designed high-speed fluid line, which enabled fast high-volume transfusion. Six 
patients survived and recovered completely. The increasing number of trauma patients treated 
with ECMO raises questions about correct indications but also effects and results of the 
treatment. There are very few animal studies performed in this field. When is ECMO 
indicated in trauma? What are the positive effects? Which negative effects and risks exists? 
What happens to the central circulation and how is coagulopathy affected? The main purpose 
of this thesis was to address some of these questions. 
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Blood activation on artificial surfaces and in extracorporeal circuits 
Introduction 
Within the blood vessel, the endothelial cells and the blood function together in a perfect 
balance, or hemostasis, but when blood is exposed to artificial biomaterials, like stents, grafts 
and cannulas, plasma proteins immediately get adsorbed to the foreign surface and a new 
interface is created between the surface and the blood. In the ECMO circuit, the circulation 
further challenges the blood by turbulence, shear stress, osmotic forces and cavitation and this 
increases the activation. Proteins in the complement system and contact pathway of coagulation 
will be bound or inserted into the protein film on the surface. The proteins generate mediators 
that activate leukocytes, monocytes and platelets. The anaphylatoxins C3a and C5a, the lytics 
sC5b-9 complex from the complement system, bradykinin and thrombin from the contact 
pathway are important examples. These mediators trigger leukocytes, monocytes and platelets 
leading to inflammation, capillary leakage and thrombotic reactions. The process is directed 
against the foreign material but the activated systems can lead to a strong inflammatory 
response that results in a capillary leakage that can cause dysfunction in all organs.  The 
inflammatory response mimics both the systemic inflammatory response syndrome (SIRS) and 
the acute respiratory distress syndrome (ARDS). This may worsen the situation for an already 
compromised patient. Thromboembolic complications following the activated coagulation 
cascade can also injure the patient or even become fatal.  
The following text focuses on how the coagulation system is activated on artificial surfaces 
such as ECMO.  Artificial surfaces induces in several processes, protein adsorption, adhesion 
of platelets, thrombin synthesis and activation of the complement system. 
Protein adsorption102, 103 
Blood is a mixture of cells and plasma. The major constituents of plasma are proteins and the 
major protein is albumin. The first event in thrombus formation on artificial surfaces is the 
adsorption of plasma proteins. Proteins can interact and undergo conformational changes in 
structure and that is an important factor for protein adsorption. This may also change the 
proteins biological activity. Fibrinogen and von Willebrand factor adsorb to the protein surface 
and facilitates platelet adhesion. Fibrinogen is replaced by FXII, HK, PPK and FXI , the contact 
pathway factors. Activation of FXII both triggers thrombin generation and activates the 
complement system. The complement and coagulation system cross talk and thrombin 
generation is amplified.  
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Cell adhesion 104, 105, 106 
Adsorbed proteins induce adhesion of platelets, leukocytes and erythrocytes to the artificial 
surfaces. Fibrinogen is the central protein responsible for platelet adhesion. The adsorption of 
fibrinogen is greater on hydrophobic than hydrophilic surfaces. Artificial surfaces activates 
platelets and they release TXA2 and ADP. TXA2 and ADP increase the platelet response on the 
surface. This results in platelet thrombus formation and with prolonged exposure of artificial 
surfaces to blood the circulating platelet count decreases. During ECMO perfusion the amount 
of circulating platelets are reduced due to adhesion and aggregation. Platelets are also injured 
but the effects of activation outweigh the injuries. A high shear rate increases the platelet 
deposition and generates FXa from TF: FVIIa. Lower shear rates reduces platelet deposition 
but instead increases fibrin deposition. A low pump speed increases the risk of thrombosis and 
clotting in the extracorporeal circuit. Leukocytes also adhere to fibrin, platelets and activated 
complement components. The leukocytes generate superoxide and free radicals but also release 
PAF, Interleukins and Tumor Necrosis Factor (TNF). These substances further activate 
platelets and induce TF expression from Monocytes. Erythrocyte adhesion is passive and not 
depending on receptor-mediated adherence as thrombocytes and leukocytes. Erythrocytes 
develop reversible echinocytic changes but can also be hemolyzed by shear forces and 
activated complement107, 108. Roller pumps cause more hemolysis than centrifugal pumps109. 
Erythrocytes can release ADP, especially during high shear stress with hemolysis, which 
further activates platelets. 
Contact activation 
The contact system factors adsorb to foreign surfaces and facilitate activation of the intrinsic 
pathway of coagulation. Several studies have indicated that catheters promote clotting via the 
contact system both in vitro110, 111and in vivo112. FXII is auto activated by negatively charged 
ions and FXIIa activates PPK and FXI. HK binds to the surfaces and acts as a cofactor, 
increasing the FXII activation. PPK activation results in Kallikrein generation, which activate 
more FXII. Activated FXI generates thrombin and results in fibrin and local platelet 
aggregation. Activated platelets further activate the coagulation system. Fibrin reinforces the 
platelet aggregates and can create a mixed platelet and fibrin thrombus. Such a thrombus can 
eventually cause the medical device to fail or separate and embolize to critical organs like the 
brain, lungs, heart or kidneys.  
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Complement activation 
The complement system is also activated when blood gets in contact with the extracorporeal 
circuit or the oxygenator113. The artificial surfaces generates PK which cleaves FXIIa to β-
FXIIa. β-FXIIa activates the C1 in the classical pathway. C3 and C5 adhere to artificial surfaces 
and are also activated by PK. C3a and C5a are attracts leukocytes and promote surface 
activation. The fibrinolytic system is early activated during ECMO114. Circulating thrombin 
stimulates endothelial cells to produce tPA, which cleaves plasminogen to plasmin. Plasmin 
causes fibrin-dissolvement and inhibits fibrinogen and V, VII, IX and XI. The cleavage 
reaction produces D–dimers, which are used as markers of clotting and fibrinolysis during 
ECMO115.  
Summary 
As a summary thrombus formation on artificial surfaces are the result of a combination of 
protein adsorption, cell-adhesion, platelet activation and aggregation. Contact initiated FXIIa 
induces thrombin generation and fibrin synthesis. The complement system is closely related to 
coagulation and is also activated on artificial surfaces. In ECMO the endogenous 
antithrombotic activity becomes overwhelmed and makes systemic anticoagulation necessary 
to withhold the extracorporeal circuits integrity (Fig. 8).  
 
 
  
Figure 8. Blood activation in the extracorporeal circuit.  
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Anticoagulation and blood-contacting medical devices  
Failure of cannulas and other medical devices is commonly due to clotting. This is caused by a 
combination of poor surface biocompatibility and flow disturbance. Improved hemodynamics 
decreases flow disruption and the risk of platelet activation. There are basically two methods of 
preventing thrombosis/clotting in blood-contacting medical devices. Synthesis of biomaterials 
with less thrombogenicity and systemic administration of anti-coagulants or anti-platelet drugs. 
Synthesis of less thrombogenic biomaterials 
Reduced protein/cell adsorption 
Polyethylene oxide (PEO)116 contains hydrophilic ether oxygen and adsorbs less proteins and 
cells than other polymers. In vitro studies are positive but there are no studies in human so far. 
Albumin coated surfaces117 adheres less platelets than fibrinogen and γ-globulin and has been 
covalently grafted onto artificial surfaces. Vascular grafts and mechanical heart valves have 
been coated with pyrolytic carbon118 and this has reduced initial platelet adhesion, but long-
term patency is similar to uncoated and patients still needs lifelong anti-coagulation with 
vitamin K antagonists. Phosphorylcholine surfaces119 resist protein and cell adhesion and have 
shown reduced platelet adhesion in animal models. Elastin is a fundamental part of the vessel 
wall and it reduces platelet adhesion. Elastin inspired polymers120 have now been linked to 
silicone with decreased fibrinogen and immunoglobulin adsorption as a result. Passive 
adsorption of an elastin polypeptide also resulted in a reduction of platelets deposited in vitro. 
The elastin-inspired polymers are promising new biomaterials. 
Inhibition of thrombin generation and fibrin formation 
Endothelial cells 
Endothelial cells have by nature anti-coagulant attributes that make them non-thrombogenic. 
Attempts to imitate endothelial cells have been made. Artificial surfaces have been seeded with 
endothelial cells with limited results. Biomaterials with bioactive molecules such as Corn 
Trypsin Inhibitor (CTI)121, heparin, and direct thrombin inhibitors have been more successful. 
A combination of Polyethylene glycol (PEG) and CTI coated surface both reduced fibrinogen 
adsorption and inhibited FXII autoactivation, reduced thrombin generation and prolonged the 
clotting time in plasma. Heparin122 and Heparin-AT  have been coated on biomaterial surfaces. 
Results from animal models are promising, but RCTs, angiographic and clinical endpoints have 
not shown any difference to uncoated surfaces123. Alginate-heparin composites on the surface 
of polyvinylchloride (PVC) may be more efficient in preventing thrombosis. DTIs (hirudin, 
bivalirudin and argatroban) have been grafted on surfaces to inhibit thrombin. They bind to 
thrombin directly in a 1:1 fashion. DTIs have been grafted onto albumin surfaces but their 
durability is questionable and in vivo data are limited. Thrombomodulin124 is a protein normally 
expressed on the surface of endothelial cells. It is a cofactor to thrombin and converts thrombin 
from a pro-coagulant to an anti-coagulant enzyme. Thrombomodulin activates protein C, which 
in turn inactivates FVIIIa and FVa. Only a few animal studies have been done with 
recombinant thrombomodulin bound to polyvinyl and polyurethane surfaces. Aspirin and 
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Clopidogrel still are the main used anticoagulants for prevention of stent thrombosis and Acute 
Coronary Syndrome (ACS). They act through inhibition of platelet aggregation and to imitate 
their effect PGI2 and PGE2 have been connected to albumin-surfaces. Finally biomaterials that 
release Nitric Oxide (NO)125 ,a potent inhibitor of platelet aggregation, have been synthesized. 
One limitation with NO releasing materials has been the relatively thick coating material 
necessary. 
Systemic administration of antiplatelet drugs or anticoagulants 
Heparin 
Optimized hemodynamics and surface-bound anticoagulation is at present not enough to 
prevent thrombosis in extracorporeal circuits and oxygenator membranes. The by far most used 
and effective systemic anticoagulant, during CPB and ECMO, is unfractionated heparin 
(UNFH). UNFH activates AT III and increases its potency a thousand fold. AT III inhibits 
thrombin, FXa and other coagulation factors. (Fig.9). UNFH creates an increased risk of 
hemorrhage, which sometimes might be fatal. In ECMO it is mainly the contact pathway that is 
activated. Therefore less anticoagulation is required than in CPB and heart surgery, where the 
tissue factor pathway also is activated.  
 
 
Figure 9. Unfractionated Heparin amplifies AT III and inhibits Thrombin and the intrinsic coagulation factors. 
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Indirect FXa inhibitors, Low Molecular Weight Heparin and Direct Thrombin inhibitors 
Fondaparinux, is an indirect FXa inhibitor and Dabigatran  is an oral thrombin inhibitor. They 
both have limited capacity to inhibit catheter-induced clotting and they are both less effective 
than UNFH and Warfarin126-128. Enoxaparin is a LMWH and  has an effect on catheter-induced 
clotting, intermediate between fondaparinux and UNFH110. Long heparin chains can inhibit 
clotting in catheters better than short chains. This is because long chains can simultaneously 
bind to AT III, FXII, FXI, FIX and FX, forming more stable enzyme-inhibiting complexes. 
Fondaparinux only binds AT III and, without inhibiting the upstream enzymes; catheters can 
induce FXa generation that overwhelms Fondaparinux. Enoxaparin can bridge the up-stream 
enzymes and is superior to fondaparinux.  
 
Novel strategies in anticoagulation of medical devices 
The aim of modern biomaterial research is to synthesize surfaces that reduce the risk of 
thrombus formation. Modern artificial surfaces are more resistant to protein- and cell adhesion. 
The protein adsorption and the activation of FXII are the primary causes of clotting in blood 
containing medical devices. In the current situation Heparin is needed either as surface bound- 
or systemically to prevent clotting in CPB and ECMO systems. An increased understanding of 
the contact pathway and complement activation in blood-contact medical device thrombosis 
may open new possibilities for both systemic and local approaches. Targeting the up-stream 
enzymes of contact activation, FXII and FXI, offers interesting anticoagulation strategies for 
the future.  
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2. AIMS OF THE THESIS 
 
 
Overall aims 
The overall aims of this thesis were:   
• To achieve higher survival for trauma patients in hypovolemic shock. 
• To develop safe anticoagulation, when treating trauma patients on ECMO.  
• To develop a novel strategy for topical hemostatics. 
  
 
 
Specific aims 
 
The specific aims of this thesis were: 
 
I) To study how central venous and arterial pressures alters during ECMO.  
 
II) To investigate if a monoclonal antibody directed against coagulation factor XIIa 
could prevent clotting in an ECMO system with preserved hemostasis.  
 
III) To study how ECMO affects coagulopathy in class IV shock. 
 
IV) To investigate how Polyphosphate induces hemostasis in a grade II liver injury. 
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3. MATERIAL AND METHODS 
 
The studies we have performed had not been possible without our study animals. The most 
sophisticated computers and software are unable to process the complicated experiments and 
interpret the full physiology of living animals. Therefore living species were unavoidable. The 
Ethics Committee for Experiments in Animals, Karolinska Institutet, Stockholm, Sweden 
approved all studies and all animals have been treated like individuals with respect and 
carefulness. 
 
Study I  
 
In study I we were interested in how VA ECMO would affect the central venous pressure and 
mean arterial pressure both in a hemodynamic normal state and a setting of increased central 
venous pressure and right ventricular load, mimicking acute lung injury. 
Ten swine (50% Yorkshire and 50% Swedish Landrace) were anesthetized and cannulated for 
venoarterial ECMO with venous cannulas for drainage in the right atrium and the inferior 
vena cava (IVC), and arterial cannula for infusion in the abdominal aorta (AA). The animals 
were connected to an ECMO system with a roller pump, a heat exchanger and a membrane 
oxygenator (Fig.10). It was custom built and identical to the clinical used models, apart from 
replacement of surface-heparinized tubing with standard tubings for economic reasons. Four 
different flow rates were used during the experiments, 5 ml⋅kg-1⋅min-1 (C0), 50 ml⋅kg-1⋅min-1 
(E1), 75 ml⋅kg-1⋅min-1 (E2) and 100 ml⋅kg-1⋅min-1 (E3). Central venous pressure in the 
superior vena cava (CVPsup) and the inferior vena cava (CVPinf), mean arterial pressure 
(MAP), portal vein pressure (Pport) and portal vein flow (Qport) were monitored and recorded 
continuously using a computer-based data acquisition system.  
 
 
Figure 10. Venoarterial ECMO. Venous blood is drained from the right atrium and inferior vena cava. 
Oxygenated blood reinfused in the abdominal aorta. Roller pump and oxygenator indicated. Arrows are reflecting 
the blood flow. The table illustrates the different settings of ECMO flow and right ventricular load.  
ECMO With normal circulation            Flow Rate 
C0: Control 0 without intervention 5 ml/kg/min 
E1: ECMO 1 without intervention 50 ml/kg/min 
E2: ECMO 2 without intervention  75 ml/kg/min 
E3: ECMO 3 without intervention 100 ml/kg/min 
 
ECMO With increased right ventricular load Flow Rate 
C1: Control 1 without intervention 5 ml/kg/min 
P1:  Increased ventricular load         5 ml/kg/min 
PE1: ECMO1 + increased ventricular load 50 ml/kg/min 
PE2: ECMO2 + increased ventricular load 75 ml/kg/min 
PE3: ECMO3 + increased ventricular load 100 ml/kg/min 
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Figure 11. ECMO blood flow and mean airway pressures reflecting the study protocol. Hemodynamic 
measurements were made a steady state at each point seen on the horizontal axis. C0 and C1 are controls 
without any intervention. P1 is a measurement with increased right ventricular load (for details see Methods) 
without ECMO. E1-E3 and PE1-PE3 are measurements with increasing ECMO flow support in three steps with 
normal and increased right ventricular load, respectively. Courtesy of Michael Broomé (Fig. 10 and 11) 
 
 
Hemodynamic steady state was reached within less than 5 minutes at each flow level. The 
flow levels were chosen as realistic levels of circulatory support in swine with expected 
cardiac outputs of 125-150 ml/kg/min, allowing some residual pulmonary circulation to avoid 
clot formation. Measurements were made not less than 10 minutes after change of flow. After 
minimizing ECMO flow, a new control (C1) was done to test the stability of the model. The 
next measurement (P1) was done after inducing a substantial increase in right ventricular load 
and venous pressures, induced by increasing positive end-expiratory pressure (PEEP) levels 
on the ventilator from 5 to 15-20 cm H2O and rapid infusion of 2-5 ml/kg of a dextran 
solution (Fig. 11). The endpoint for this intervention was a CVPsup of 15 cm H2O and a 
substantial decrease in MAP to about 60 mm Hg. After this measurement, the ECMO flow 
was increased stepwise to the same levels as in the first stage of the study while maintaining 
the ventilator settings and the volume load to simulate a clinical situation with increased right 
ventricular load. Measurements were at each level of ECMO flow (PE1-PE3) as before. 
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Study II 
 
In study II a recombinant fully human antibody (3F7) that binds into the FXIIa enzymatic 
pocket was investigated. Of particular interest was if 3F7 could provide thromboprotection in 
the extracorporeal circuit as efficient as Heparin, but without impairing the hemostatic capacity. 
An ECMO-system that is normally used for pulmonary and circulatory support for infants was 
adapted for rabbits. 15 New Zealand White rabbits were divided in three groups with 5 rabbits 
in each group. The control group received Saline instead of anticoagulation, the Heparin group 
received unfractionated heparin (UNFH) in identical doses as those used in ECMO-patients and 
the Test group received 3F7 (7mg/kg).  
 
Thromboprotection 
 
In the circuit, the oxygenator is the most critical part for clotting (thrombus formation). The 
blood pressure gradient between the inlet and outlet of the oxygenator was controlled as a 
measure of occlusive thrombus formation. The blood clotting in the oxygenator was also 
controlled with Scanning Electron Microscopy (SEM) after 6 hours of ECMO. The amount of 
fibrin deposited in the oxygenator was quantified both visually from high power field images 
(HPF) and by Western blotting using a fibrin-specific antibody. 
 
Bleeding 
 
The rabbits hemostatic capacity were analyzed via incision-triggered bleeding times and blood 
loss from injury site at the end of the ECMO procedure. We used skin-bleeding time in the ear 
(Surgicut® jr), cuticle bleeding time and cuticle bleeding volume. 
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Study III 
In study III it was investigated how VA ECMO affects Traumatic Induced Coagulopathy (TIC). 
15 New Zealand White Rabbits were used in an experimental trauma model with bilateral femur 
fractures, laparotomy and a class IV bleeding shock (>40% hemorrhage of blood volume). The 
hemorrhagic shock lasted for 90 minutes Five of the study rabbits, the control group, were treated 
with a standard transfusion protocol (transfusion of whole blood, calcium and active rewarming). 
Another five rabbits, the ECMO group, received the same treatment as the former group but were 
also on venoarterial ECMO for 60 minutes (Fig.12). The ECMO system was designed as 
described in Study II. Finally five rabbits were used as blood donors for priming the ECMO-
circuits (one rabbit/circuit). The circulatory status (HR, MAP), acid-base balance (pH, Lactate 
and BE) and temperature were controlled every 15 minutes. The coagulation capacity and 
bleeding were controlled at base line (0 min), after 90 minutes of bleeding shock and after 
another 60 min of resuscitation (at 150 min). Coagulation was controlled with rotational 
thrombelastometry (ROTEM), platelet count, aPTT, INR and fibrinogen. In vivo bleeding was 
controlled with ear bleeding time and cuticle bleeding time. 
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Figure 12. The Rabbit ECMO-Trauma model. The animals sustained laparotomy and bilateral femur fractures and 
were exsanguinated to class IV Shock. The hemorrhagic shock lasted for 90 min and the following resuscitation for 
60 min. The ECMO circuit: Venous draining cannula in the right atrium (blue), roller pump, heparinized membrane 
oxygenator for saturation and carbon dioxide removal, water heat exchanger (38.5°C). Blood is reinfused in the 
descending aorta (red). 
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Study IV 
In study II the antibody 3F7, which systemically inhibits FXIIa, was evaluated according to its 
thromboprotective effect in an ECMO system. A severely injured patient on ECMO may still 
benefit of a local activation of FXII for clotting. Polyphosphate (PolyP) is a linear molecule 
consisting of PO42- (phosphate-ion) chains and it is released from platelets when they are 
activated in vascular injuries. PolyP has hemostatic properties by initiating the intrinsic pathway 
of coagulation. PolyP activates FXII, the Hageman factor.  In study IV PolyPs hemostatic effect 
in vivo on grade II liver injuries in swine were controlled. The synthetic PolyP we used 
resembled platelet PolyPs and had a chain length of 70-100 units. Ten swine were used in the 
study. Incisions in each of three liver lobes were performed (3 cm long and 1 cm deep). The 
amount of bleeding from each liver injury was controlled to be macroscopically equal and then 
Total Vascular Exclusion (TVE), by occlusion of the infra- and suprahepatic IVC, the portal vein 
and hepatic artery (Pringle’s maneuver) was performed for 3 minutes. During this time the liver 
wounds were not bleeding at all and meanwhile three different agents in powder form were 
applied. 500 mg Kaolin (K), triphosphate (P3) or PolyP were used. The surgeon was blinded to 
the powder type. The wounds were randomly filled ensuring that one powder was not always 
placed in the same injured liver-lobe. After 3 minutes the liver-circulation was restored. All 
wounds were compressed manually for 10 minutes including the time for TVE (Fig.13). When 
the pressure was relieved the bleeding was photographed and the macroscopic coagulation was 
judged to be non-bleeding (0), minor bleeding (1) or major bleeding (2). Major bleeding was 
defined as when the rate of bleeding was the same as before the hemostatic agent was applied. 
The compress material from each wound was weighted. The hemoglobin from each wound was 
measured with spectrophotometric absorbance and the true blood-loss from each injury was 
calculated. Before termination of the swine thorough excisions of the liver-wounds were made to 
obtain specimens for immunohistochemistry and electron microscopy. The liver excisions were 
made at two time points, 30 min and 4 h after injury, and after this the animals were sacrificed. 
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Figure 13. The liver injury model. Grade II liver injuries were treated with Kaolin, PolyP and P3 respectively. 
Bleeding was visually registered after 10 min of compression. 
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4. RESULTS AND DISCUSSION 
Study I 
Results study I Part I. Effects of ECMO in a normal hemodynamic state: C0-E3 
Veno arterial ECMO increased MAP and reduced CVPsup, while HR, Qport, Pport and CVPinf did 
not change significantly. Central venous oxygen saturation (SvO2) increased and end tidal carbon 
dioxide (etCO2) decreased reflecting an increase in systemic perfusion with reduced pulmonary 
blood flow (Fig.14).  
Results  Study I Part II. Effects of ECMO with increased right ventricular load: PI- PE3. 
Venoarterial ECMO increased MAP and Qport and reduced both CVPsup and CVPinf  while HR and 
Pport remained unchanged during the experimental stage with increased right ventricular load. 
SvO2 increased and etCO2 decreased as in part (Fig.14). 
  
Figure 14 abc. Hemodynamic data reflecting changes induced by increasing ECMO flow. Mean arterial pressure 
increased significantly both during a normal circulatory state (Fig.14a, E1-E3) and with increased right ventricular 
load (Fig.14a, PE1- PE3). Similar circulatory changes are seen in portal venous flow (Fig.14 c, E1-E3 and PE1-PE3). 
Central Venous Pressure is decreased with increased ECMO flow during both stages (Fig. 14 b, E1-E3 and PE1-
PE3), reflecting the unloading of the venous system. Courtesy of Michael Broomé. 
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Discussion study I 
The main finding of the experiment was the reduction of central venous pressures (CVPsup  and  
CVPinf ) with increasing venoarterial ECMO flow. Portal flow and systemic blood pressure were 
improved during increased right ventricular load. A decrease in venous pressure (CVPsup) was 
noted in the stage with normal right ventricular load, while the effect on systemic perfusion was 
less pronounced in this setting. Both Portal flow and Mean Arterial Pressure increased to normal 
or even supernormal levels, indicating unnecessary hypervolemia. In the clinical situation with 
ongoing hemorrhage, the fluid resuscitation would be limited according to the concept of 
permissive hypotension129. The ECMO cannulation technique used in this study may be useful 
for solving other surgical problems as well. Blood is drained from both the SVC and the IVC. 
Oxygenated and normothermic blood is infused in the aorta with a flow rate approaching normal 
cardiac output if required. Blood flow and pressure in the pulmonary circulation are reduced 
during VA ECMO130. This may limit bleeding from large pulmonary vessels and possibly 
decrease the need for pulmonary resections131. The IVC can be clamped without compromising 
venous return or causing venous congestion in the abdominal organs or lower extremities. An 
injury to the retrohepatic IVC or hepatic veins is lifethreatening to the patient and extremely 
difficult for the trauma surgeon. Combined with ECMO, total hepatic vascular exclusion (TVE) 
may be applied with preserved systemic perfusion132, 133.  The short-term risks with ECMO 
include bleeding complications during cannulation, bleeding caused by tube disconnection, 
cannule displacement and air or clot embolization. These risks are reduced with the growing 
experience of a dedicated ECMO team. Short perfusion time in most trauma patients reduces the 
risk of infections and coagulation disorders. In this study systemic heparin was used due to 
economic reasons. In the clinical trauma situation however, surface heparinized circuits would be 
the equipment of choice. 
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Study II 
Results study II 
Thromboprotection. The pressure gradient over the oxygenator 
In the control (saline) group no anticoagulation was used in either animals or ECMO system. 
Without anticoagulation the pressure gradient over the oxygenator rapidly increased to > 500 
mmHg, the roller pump failed to maintain circulation, and within < 3 min, the extracorporeal 
circulation was completely occluded. In two other control rabbits it was impossible to drain blood 
into the ECMO system because of thrombotic occlusion of the cannulas. In contrast Heparin 
efficiently inhibited occlusion of the cardiopulmonary bypass system. The blood pressure over 
the oxygenator remained low (<15 mm Hg) throughout the 6-hour ECMO run. A single dose of 
3F7 administered 5 min prior the start of ECMO provided similar thromboprotection to that 
observed with Heparin. In the 3F7 group the pressure gradient over the oxygenator also was < 15 
m Hg (Fig.15 A). Arterial oxygen saturation (SO2) reached 100% in both the heparin- and 3F7 
groups and was stable throughout the 6-hour ECMO period indicating normally functioning 
oxygenators. 
 
        
 
 
 
Figure 15 A. Changes in the oxygenator pressure.  
The rabbits were pretreated with a single bolus of saline, heparin or 3F7, 5 min before the start of ECMO.  
The blood pressure gradient over the oxygenator was continuously monitored at the inflow and outlet by a  
pressure sensor. 
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Thromboprotection. The fibrin deposition in the oxygenator 
SEM examination of the opened oxygenators revealed large clots of fibrin and deposited blood 
cells in the Saline treated group (Fig.15 B-C) already after the first minutes of perfusion, whereas 
fibrin depositions after 6 hours were minimal in oxygenators of Heparin- and 3F7-treated rabbits 
(Fig. 15 D-G). When quantified in SEM it was found that the fibrin deposits were significantly 
reduced in both Heparin and 3F7-treated animals compared to saline controls (p<0.005)  
(Fig 15 H). Oxygenator extracted material was analyzed for fibrin deposition by Western blotting 
and consistent with the SEM images the fibrin signal was high in the saline treated group and 
largely reduced in the Heparin- and 3F7 anticoagulated systems (Fig.15 I).  
 
 
 
 
 
   
 
 
 
 
Figure 15 B-I. Scanning Electron Microscopy of oxygenator capillaries (15B-G). Quantification of fibrin deposition 
per HPF (15H). Western blot analysis of fibrin signal from oxygenator clots (15 I). 
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Bleeding in vivo 
Heparin treatment largely prolonged incision-provoked skin bleeding time in rabbits from 130 ± 
15 to >600 s (Fig. 16 A). Heparin also impaired hemostasis at wound sites induced by clipping 
the cuticle tip after 6 hours of extracorporeal bypass. Cuticle bleeding time was >600 s and 
accompanied by a mean blood loss of 5.1±1.1 ml (Fig16 B and C). In contrast, the hemostatic 
capacity of 3F7-treated rabbits was intact. 3F7-treated rabbits had similar mean bleeding times as 
saline-infused controls (skin: 160 ± 40 s versus 130 ± 15 s and cuticle: 165 ± 40 s versus 120 ± 30 
s) (Fig. 16 A-B). Blood loss from cuticle wounds was also not significantly increased over that of 
saline-treated animals (0.2 ± 0.05 ml/10 min versus 0.3 ± 0.1 ml/10 min) (16 C). 
 
Figure 16 A-C. Differential effects of 3F7 and heparin on hemostasis. Skin bleeding time (A), Cuticle bleeding 
time (B) and Blood loss from cuticle (C). 
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Discussion study II 
Anticoagulant therapy is one of the most common forms of medical intervention and used for 
treatment and prevention of thrombosis. Bleeding is the primary complication of anticoagulant 
therapy and a significant risk of all currently used anticoagulants, even when maintained within 
their therapeutic ranges134, 135 Heparin is obligate as clot prevention in ECMO and bleeding is 
also the most frequent and severe complication of ECMO-treatment136. The present study shows 
a safe thromboprotective strategy based on inhibition of FXIIa activity in a clinically meaningful 
setting. The anti-FXIIa antibody 3F7 is as efficient as heparin for thromboprotection in an ECMO 
system, but without the heparin-associated impairment of hemostatic capacity. Humanized 
antibodies expressed in mammalian cells have been used clinically for many years and are an 
important class of human therapeutic products137. The fully human 3F7 antibody is expected to 
display minimal immunogenic potential, and the long serum half-life is ideal for prophylactic use. 
3F7 has the necessary properties for further analysis as a mode of safe anticoagulation in clinical 
trials. Over the past 40 years, more than 69000 patients have been treated with ECMO, and the 
modified heart-lung machine has salvaged many lives by providing gas exchange and systemic 
perfusion. However, the ECMO circuit exposes blood to non-physiological surfaces that directly 
induce FXII contact activation leading to coagulation and complement-activated inflammation. 
Currently heparin is the standard anticoagulant in ECMO. Heparin increases bleeding, which is 
the principal cause of morbidity and mortality in ECMO therapy and stresses the need for safer 
anticoagulation. Although coating the gas-exchanging capillaries in oxygenators with heparin138, 
phosphorylcholine139 or fibronectin140 has improved the biocompatibility, there is a continuous 
FXIIa generation on bypass circuit surfaces141. Non-physiological shear and mechanical forces 
activates platelets in the bypass circulation. Activated platelets release the inorganic polymer 
Polyphosphate, which provides an alternative source of FXIIa generation with implications for 
fibrin production within the growing thrombus142. Nitric Oxide inhibits platelets and provides 
thromboprotection in experimental ECMO systems125, 143. In contrast, 3F7 interferes with both 
artificial surface- and platelet-produced procoagulant FXIIa activities. 
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Study III 
 
Results study III 
 
The Hemorrhagic Phase 
After traumatic injury and 90 minutes of hemorrhagic shock, all animals (n=10) were in a critical 
state and fulfilled the set criteria of hypotension (MAP<20 mmHg), hypothermia (T<32°), 
metabolic acidosis (pH<7.3) and coagulopathy. There was no significant difference in acidosis 
(BE, lactate or pH), temperature, hemodynamic status (HR, MAP) or ROTEM between the two 
groups after the 90 minutes of traumatic hemorrhage. The hematocrit did not differ between the 
two groups after hemorrhage and resuscitation (p=0.84) indicating that the hemorrhage and 
transfusion protocols were equal (Fig.17) 
 
 
 
Figure 17. The Hematocrit during the study. The exsanguination and retransfusion in the two groups were equal. 
Control (−−−) ECMO ( -----) 
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The Resuscitation phase 
Hemodynamic status 
Immediately after initiation of ECMO the HR and MAP improved and after 60 min the animals 
were back to a normal circulatory state. In the control group the HR kept falling after 
resuscitation and MAP increased during the first 30 min but never exceeded 40 mm Hg and then 
decreased again. There was a statistical significant difference, favoring the ECMO  
group, after 60 minutes of resuscitation both according to HR and MAP  
(p=0.01 and p=0.01 respectively) (Fig. 18 A-B). 
 
18 A    18 B 
 
Figure 18. The animals circulatory status during the study. 90 minutes after hemorrhagic shock there was no 
difference in heart rate (Fig.18A) or mean arterial pressure (Fig. 18B) between the two groups but after 60 min of 
resuscitation the heart rate and mean arterial pressure in the ECMO group were significantly improved.  
(p=0.01 respectively). Control (−−−) ECMO (----). 
 
Acid-Base balance 
There was a significant rise in lactate (>8mM), decrease in BE (-10) and fall in pH (<7.3) in both 
groups at the end of hemorrhagic shock phase. The lactate concentration slowly started to fall 
after initiation of ECMO but continued to rise in the control group (>12mM). After the 
resuscitation phase for 60 min lactate was overall significantly lower in the ECMO group 
(p=0.01). Base Excess started to increase after 30 minutes of ECMO treatment and was overall 
significantly improved compared to the control group (p=0.01) (Fig. 19 A). After 20 min of 
ECMO, pH started to increase and was above 7.0 after 60 min. Meanwhile the pH continued to 
be low in the control rabbits (<6.9) the pH after 60 min was significantly higher in the ECMO 
group (p=0.01) (Fig.19B). 
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19 A    19 B 
Figure 19. The animal’s acid-base balance during the study. 90 minutes after hemorrhagic shock there was no 
difference in base excess (Fig. 19A) or pH (Fig.19B) between the two groups. After 60 min of resuscitation the base 
excess and the pH were significantly higher in the ECMO group (p=0.01 respectively).  
Control (−−−) ECMO (-----). 
Body temperature 
Initiation of ECMO efficiently increased the animal’s body temperature and after 60 minutes of 
active warming they had reached their initial temperature (>37°C), which was significantly 
improved, compared to the control group, where the body temperature remained low (below 30 
°C) despite warm blood transfusion (p=0.01) (Fig.20). 
 
Figure 20. The animals body temperature. Initiation of ECMO increased the animal’s body temperature efficiently 
and after 60 min the animals in the ECMO group were significantly warmer (>37 ° C) than the controls (p=0.01). 
Control (−−−) ECMO (----). 
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Coagulation In Vitro (Table 1) 
The contact pathway of coagulation was evaluated with aPTT and ROTEM Clotting Time, 
(CTIntem). The aPTT decreased in the ECMO group during the 60 min of resuscitation (17.7 ± 
2.7s – 11.0 ± 2.3 s), while aPTT, in the control group, continued to rise (20.6 ± 4.3 s – 29.0 ± 
8.7s). The difference between the two groups did not reach statistical significance (p=0.07). 
CTIntem increased in both groups, but even though there was no significant difference at the end of 
resuscitation, the rise was higher in the control group, control: 948 ± 693 s vs. ECMO: 290 ± 93 
s.  
The tissue factor dependent extrinsic pathway of coagulation was analyzed by INR, ROTEM 
(CTExtem ) and (CFTExtem). INR decreased after 60 min of ECMO (1.74 ± 0.33 - 1.44 ± 0.2) while 
it remained on the same level in the control group (1.3 ± 0.15 - 1.36 ± 0.09). The extem clotting 
time (CTExtem) was considerably reduced in the ECMO group (764 ± 687 - 79 ± 8 s) while it was 
largely prolonged in the control group (69 ± 4 - 764 ± 687s) and there was a difference between 
the groups at the end of the experiment. Control clotting time was 764 ± 687s versus ECMO 
clotting time 79 ± 8 s (p=0.17).  
The clot formation time (CFTExtem) followed the same pattern with a clear decrease in the ECMO 
group (1141 ± 965 - 111 ± 19 s) and a clear increase in the control (170 ± 14-1770±1001s). The 
extrinsic clot formation time was at the end significantly lower in the ECMO group (p<0.01). 
Analyzing the clot firmness with ROTEM gave the following results. MCFExtem (reflecting both 
platelet and fibrinogen contribution) was slightly increased after ECMO for 60 min. (42.2 ± 
10.4mm - 51.6 ± 2.8 mm) while it was reduced in the control (51.2 ± 0.9 mm- 35.6 ± 10.6 mm). 
The difference was not significant (p=0.2). The MCFFibtem (only fibrinogen contribution) showed 
minimal detectable values at the end of the experiments equally in both groups. The Fibrinogen 
levels were also equally diminished in the two groups and did not increase after transfusion. 
Neither in the study group nor in the control group the ROTEM curves showed any fibrinolysis. 
Analyses with HEPTEM, blocking heparin effect, did not change the INTEM CT or CFT 
variables, confirming that there was no heparin effect in the system.   
The platelet count was equal in the two groups initially but after 90 min of hemorrhagic shock the 
platelet count was lower in the ECMO group. The number of circulating platelets kept falling and 
was at the end of the resuscitation phase significantly reduced in the ECMO group (85 ± 17) 
compared to the control group (149 ± 20) (p=0.02). 
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 Baseline 
0 min 
Control 
90min 
ECMO  
90 min 
   P1 
      
Control  
150 min 
ECMO 
150min 
  P2      
Temp (°C) 38.4 ± 0.1  30.3 ± 0.4  30.7 ± 0.2 0.34   29.3 ± 0.4   37.3 ± 0.3 0.01 
pH 7.44 ± 0.01 7.20 ± 0.04 7.16 ± 0.10 0.38 6.90 ± 0.03  7.08± 0.04 0.01 
Lactate (mM) 1.07 ± 0.05  11.6 ± 1.4  8.9 ± 1.1 0.10   14.3 ± 1.1   7.8 ± 0.7 0.01 
BE (mM) 2.79 ± 0.03 -12.3 ± 1.8 -14.3 ± 2.3 0.26  -21.4 ± 0.5 -16.2 ± 1.0 0.01 
Hb (g/L)  134 ± 3     56 ± 4     62 ± 3 0.17      90 ± 16     93 ± 8 0.45 
PLT x 109 /L  193 ± 17   131 ± 23     93 ± 18 0.17    149 ± 20    85 ± 17 0.02 
aPTT (s)  14.4 ± 2.6   20.6 ± 4.3   17.7 ± 2.7 0.16    29.0 ± 87  11.0 ± 23 0.07 
INR   0.9 ± 0.0  1.3 ± 0.15 1.74 ± 0.33 0.20 1.36 ± 0.09 1.44 ± 0.2 0.42 
Fibrinogen   2.2 ± 0.0  1.2 ± 0.3   0.9 ± 0.2 0.38     1.3 ± 0.2   1.0 ± 0.2 0.38 
CTExt (s)    45 ± 2   69 ± 4   764 ± 687 0.04   827 ± 710    79 ± 8 0.17 
CFTExt (s)    42 ± 1 170 ± 14 1141 ± 965 0.46 1770±1001  111 ± 19 0.01 
MCFExt(mm) 66.7 ± 0.5 51.2 ± 0.9 42.2 ± 10.4 0.30 35.6 ± 10.6 51.6 ± 2.8 0.20 
CTInt (s)  181 ± 28  262 ± 357   245 ± 64 0.46   948 ± 693  290 ± 93 0.34 
MCFFib(mm) 11.3 ± 0.5   4.0 ± 0.3    4.2 ± 1.0 0.33    3.4 ± 1.0   4.8 ± 1.0 0.19 
EBT (s) 66.0 ± 9.0        -        -    -   162 ± 21    55 ± 7 0.01 
CBT (s) 70.5 ± 10.5        -        -    -   174 ± 15    75 ± 13 0.01 
Coagulopathy*      No      ++      +++        ++         +  
Table 1. Blood and coagulation. Baseline represents all animals. The control and ECMO groups are compared after 
hemorrhagic shock (90 min) and after resuscitation (150 min) and p-values are calculated with Rank Sum Test.   P1: 
90 min P2 : 150 min Values presented as Means with SEM. *) Coagulopathy defined as aPTT > 26s 
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Coagulation In Vivo (Table 1.) 
The baseline bleeding times according to Ear Bleeding Time (EBT) and Cuticle Bleeding Time 
(CBT) were equal in the two groups. After resuscitation the EBT was increased to162± 21 and 
the CBT to 174 ± 15 s in the control group. In contrast, the hemostatic capacity of ECMO-treated 
rabbits was improved with an EBT of 55±7s and a Cuticle mean bleeding time of 75 ± 13 s. Both 
the difference in EBT (p=0.01) and CBT (p=0.01) were statistically significant, favoring the 
ECMO group. 
Outcome and Survival 
In the ECMO group three animals (3/5) were asystolic and one was severely bradycardic 
(HR<10) at cannulation. They all received external cardiac compressions and recovered with 
recapture of sinus rhythm and normalized blood pressure after transfusion and initiation of 
extracorporeal circulation. In summary all animals (5/5) in the ECMO group survived with 
stabilized vital status and improved coagulation. Two animals (2/5) in the control group were 
asystolic, 28 min respectively 30 min after initiation of resuscitation (transfusions were 
completed in both cases). They received external cardiac compressions but did not regain sinus 
rhythm. The surviving animals in the control group (3/5) were all in a deranged circulatory status. 
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Discussion study III 
Trauma-induced coagulopathy is an important reason for death in trauma victims78. Tissue injury 
and systemic hypoperfusion are needed for the development of acute traumatic coagulopathy64 
(ATC). When fully developed, coagulopathy is very difficult to reverse. This study shows that 
VA-ECMO improves acidosis and temperature in a traumatic experimental hemorrhagic model. 
The animals were efficiently rewarmed (>37°C) and could reach a pH above 7.0 within 60 min. 
ECMO also improved central circulation in terms of blood pressure and heart rate. When 
supported by VA-ECMO all animals in severe hemorrhagic shock survived. The extrinsic 
coagulation pathway reflected by clot formation time (CFTExtem ) was improved and there was a 
trend of improvement in the intrinsic pathway as well. These findings were verified with skin and 
cuticle bleeding times.  
To our knowledge no similar study has been performed before. We have used the rabbit-ECMO 
model before when evaluating the Factor XII antibody 3F7144. ECMO has previously been used 
in a rabbit-trauma model where ECMO-resuscitation for prolonged hemorrhagic shock (3h) 
improved tissue perfusion, reduced systemic inflammation and alleviated the intestinal damage 
that may be one important factor for multi organ failure (MOF)145. Park et al showed that rats 
exposed to both hemorrhagic shock and hypothermia have a prolonged clot formation time and 
reduced MCF146. The former finding is verified by the present results, but ECMO only slightly 
improved the clots firmness. This may be due to the consumption of fibrinogen. The fibrinogen 
levels were equally reduced after hemorrhagic shock in both groups and the ECMO system did 
not seem to aggravate fibrinogen consumption. Apart from a lower platelet count and much 
higher CTExtem and CFTExtem in the ECMO group after hemorrhagic shock there was no difference 
between the groups before resuscitation.   
In spite of the initial advanced coagulopathy, several coagulation parameters improved after 
ECMO-resuscitation. Engstrom et al showed the importance of an increased pH and reduced 
lactic acidosis to avoid impairment of the coagulation cascade in two previous studies147, 148 We 
believe that the improvement of tissue perfusion with ECMO resulted in a gradual normalization 
of lactate and pH. This may have had a beneficial effect on the coagulation capacity. To gain 
efficiently strong clots after this type of trauma it may be necessary to substitute fibrinogen. In 
the present study the fibrinogen levels were consumed, stayed on a low level and was not 
substituted. This was verified by a reduction of the maximum clot firmness in both MCFExtem and 
MCFFibtem . These findings suggest that the reduction was due mainly to low fibrinogen levels. In 
a clinical setting fibrinogen would have been substituted. Extracorporeal devices activates the 
coagulation system149 and previous studies have shown decreased numbers of circulating platelets 
in extracorporeal devices150, 151. This finding was confirmed in the present study. The number of 
circulating platelets did not reach levels below 50x109/L and the clotting ability did not seem to 
be negatively affected. In vivo testing of the coagulation capacity with ear bleeding and cuticle 
bleeding times showed an improvement in the ECMO group.  
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ECMO in trauma has been somewhat controversial but has in recent years gained in popularity 
both in the post trauma ARDS situation and in hypovolemic shock during the early resuscitation 
phase101. In our clinical experience, we have successfully resuscitated selected patients with 
respiratory failure and concomitant hemorrhagic shock due to thoraco-abdominal trauma with 
venoarterial ECMO (non published data). An earlier experimental study described how VA-
ECMO reduced systemic venous pressure while maintaining or improving systemic perfusion in 
both a normal circulatory state and in the setting of increased right ventricular load associated 
with acute lung injury152. ECMO may theoretically be a useful tool in reducing blood loss during 
major venous hemorrhage, but other positive or negative effects of ECMO in trauma need to be 
investigated. There have been concerns about using heparin in trauma patients on ECMO. We did 
not use systemic heparin as anticoagulant for the ECMO system but heparinized surfaces of 
tubings and oxygenators. Viscoelastic heparin test (HEPTEM) did not show any increase of free 
heparin in the system. There was a trend of improved aPTT in the ECMO group and there were 
no problems with clotting in the circuit. In the future it may be possible to use anticoagulant 
drugs that do not affect the bleeding risk144. 
The effects of ischemia-reperfusion in our study were not controlled but these effects were 
assumed to be equal in both groups. Inflammation and coagulation are largely activated in 
ECMO-systems 153. The aim was to study the effect of ECMO support in the first initial 60 min 
of trauma resuscitation. The ability of ECMO to fast increase the body temperature during this 
time is obvious but the reduction of lactate and improvement of pH is somewhat slower. If 
ECMO had been extended for more than 60 minutes, maybe even continued for the first 24 post-
trauma hours, the acid-base balance might have been improved further. A suboptimal ECMO 
flow, 100ml/ min instead of 300ml/ min, was used because of the limited amount of blood to 
prime the ECMO circuits. In clinical trauma scenarios there may be a continuing bleeding 
problem and difficulties to withhold a full flow.  However, the ECMO circuit can be filled with 
as much blood as required, and the large bore cannulas are optimal for high volume infusion. This 
study was limited of some technical factors including the preparation of tracheostomy and 
laparotomy before the trauma and the priming of the ECMO circuit before the actual   experiment 
started. The coagulation system in rabbits is slightly different compared to humans. The rabbit 
coagulation system is constructed as the human with extrinsic, intrinsic and a common pathway´s 
and consists of the same coagulation factors. The serine proteases activity differs though. Rabbits 
have a 50 times higher activity of factor V than humans and the activity of factor XI and factor 
XIII are also slightly higher. This may explain why rabbits have shorter aPTT and PT154. The 
different activity may limit implications for human management and the variations of our 
coagulation data may be explained by a limited time of ECMO-resuscitation and a rather small 
number of study animals. However, this is the first experimental study showing ECMO’s effect 
on temperature, acidosis and coagulation in an animal model of trauma and hemorrhage. Further 
studies to evaluate ECMO’s role in trauma are obviously needed and indications for venoarterial 
ECMO in severe trauma need to be established in collaboration between the trauma- and ECMO 
communities.  
In conclusion, VA-ECMO seems beneficial in an experimental traumatic hemorrhagic shock 
model for stabilization of central hemodynamics, improvement of acidosis, body temperature and 
coagulopathy.  ECMO may also increase the likelihood of survival.  
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Study IV 
 
Results study IV 
Polyphosphate enhances thrombin generation in a FXII dependent manner  
PolyP was able to enhance thrombin generation in plasma. PolyP was equally efficient as Kaolin 
and significantly better than P3 (Fig. 21A). The lag time to thrombin generation was 2.58 ± 0.25 
min for PolyP and 10.75 ±0.42 min for P3 and was significantly shorter (p<0.004). The time to 
thrombin peak was also shorter for PolyP 5.00 ± 0.01min compared to 14.50 ± 0.67 min for P3 
(p<0.005). The amount of generated thrombin was significantly greater when PolyP (846.5 ± 99.5 
nmol) was compared to P3 (334.0 ± 5.0 (p=0.035). There was no difference when PolyP was 
compared to Kaolin. (Fig. 21 B-D). 3F7, the FXIIa inhibiting antibody 3F7 completely abolished 
PolyPs thrombin potential. Values are expressed as Mean ± SEM.  
 
 
Figure 21. Real Time Thrombin Formation: PolyP was equally efficient as Kaolin to induce thrombin generation 
(Fig.21 A) The lag time to thrombin generation (Fig.21B) and the time to peak (Fig.21D) was significantly shorter 
with PolyP compared to the control P3 (p<0.004**) Fig.21B and respectively (p<0.005**) (Fig.21D). The amount of 
generated thrombin was also significantly increased with PolyP compared to P3 (p=0.035**) (Fig 21C). There was no 
difference when PolyP was compared to Kaolin according to thrombin generation time or amount (Fig.1B-B*). 3F7, 
the FXIIa inhibiting antibody totally abolished polyPs thrombin potential, indicating that polyP drives thrombin 
formation by activating FXII (Fig.21A). 
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Polyphosphate is hemostatic in liver injury 
Visually PolyP had a better coagulative effect than P3 [0.7 ± 0.2 versus 2.0 ± 0.0] (p=0.0007*). 
The visual bleeding in PolyP-treated wounds was comparable with that of Kaolin treated wounds 
[0.5 ± 0.2] (Fig 22A). Without reaching significant difference, there was a trend that the compress 
material from PolyP and Kaolin treated wounds were lighter compared with P3** [2.1 ± 0.6 g, 
1.9 ± 0.7 g and 3.3 ± 0.6 g (P3)] (Fig 22B). When blood loss was calculated through hemoglobin 
amount in compress material, PolyP–treated wounds bleed significantly less (p<0.0002***) than 
control (P3) [0.1 ± 0.03 g versus 1.66 ± 0.45 g]. The blood loss from the PolyP treated wounds 
was comparable to the Kaolin-treated wounds [0.1 ± 0.03 g versus 0.1 ± 0.04 g] (Fig 22 C). 
 
        *              **                *** 
 
Figure 22. Polyphosphate is hemostatic in liver injury. A: Visual Bleeding Score (0-2), B. Blood loss      
according to compression weight (g), C. Calculated blood loss by measured hemoglobin (g) 
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Polyphosphate enhances fibrin clot structure at the wound site 
Scanning Electron Microscopy (SEM) showed an irregular non-organized structure of fibrin 
fibrils in Kaolin treated wounds. P3-treated wounds had thin loosely connected fibrils, whereas 
PolyP-treated wounds had fibrils that were thick and gave a reinforced impression. Fibrin clots in 
the presence of PolyP, revealed thicker fibrils than clots made without PolyP. The fibrin fibrils in 
PolyP-treated wounds were significantly thicker than both control- and Kaolin-treated wounds, 
(p<0.0001* and p<0.0001** respectively)  [258 ± 63nm, 94 ± 18nm and 192 ± 44 nm]  
(Fig. 23 A-G).  
 
          **        * 
  
Figure 23. SEM examination of fibrin clots from liver wounds: Polyphosphate enhances the fibrin clot structure. 
Fibrin fibrils in Kaolin treated wounds showed an irregular non-organized structure (Fig.23B-C), PolyP-treated 
wounds showed fibrils that were thick and gave a reinforced impression (Fig.23D-E). P3-treated wounds had thin 
loosely connected fibrils (Fig.23F-G). The fibrin fibrils in polyP-treated wounds were significantly thicker than P3 
treated wounds (p<0.0001*) (Fig.23A). 
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Polyphosphate has minor inflammatory effects at the wound site  
30 min after the liver injuries were treated the number of infiltrating neutrophils were 
significantly higher in the wounds treated with P3 compared to the wounds treated with PolyP 
and Kaolin [201±25, 109±13 and 123 ±22] (p<0.0001) (Fig. 24 A** and ***). 
4 h after treatment of the liver injuries the number of infiltrating neutrophils was significantly 
lower in the PolyP-treated wounds compared to both Kaolin-treated (*) and controls [85±37, 
172±47 and 173±12] (p<0.0065). In Kaolin-treated wounds the neutrophil level was significantly 
increased 4 hours compared to 30 min after treatment [172±47 versus 123±22] (p<0.01). At this 
time the liver cells were more separated in both Kaolin- and PolyP- treated wounds Fig (24 B).  
 
 
 
Figure 24. Polyphosphate has minor inflammatory effects at the wound site. Immunohistochemistry 30 min  
(Fig. 24A) and 4 h after treated liver injuries (Fig. 24B). 30 min after the liver injuries were treated the number of 
infiltrating neutrophils were significantly higher in the wounds treated with P3 compared to the wounds treated with 
polyP and Kaolin (p<0.0001 respectively) (Fig. 24A ** and ***). 4 h after treated liver injuries the number of 
infiltrating neutrophils was significantly lower in the polyP-treated wounds compared to both Kaolin-treated  
(Fig. 24B*) and controls [85±37, 172±47 and 173±12] (p<0.0065).  
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Polyphosphate is degraded in blood, plasma and serum  
PolyP was stable in water and PBS for at least 16 days. PolyP was degraded at an equal rate in 
blood, plasma and serum. PolyP had a half-life of 2.5 h in swine plasma (Fig. 25A) and 4 h in 
human plasma (Fig. 25B). After 4 days it was not traceable any more.  
 
 
 
 
 
25 A      25 B 
Figure 25. Degradation of long-chained PolyP. Swine Blood, Plasma and Serum (25A). Human Blood, Plasma and 
Serum (25B). 
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Discussion study IV 
The principle of creating hemostasis with biochemical agents is far from new. Hemostatic 
Agents (HA) have been used by several ancient cultures. The Egyptians treated bleedings with 
topical applications of raw meat as early as 1600 B.C. 155 and at the time of Hippocrates (460-
377 B.C.) cupper sulfate was used to induce artificial hemostasis. Today we know more about 
the mechanisms of coagulation and we still use the same principals as our ancestors did. What 
hemostatic mechanism, the Egyptian meat was driving remains unknown. One might speculate 
if the external provided Tissue Factor (TF) might have induced the TF: FVIIa coagulation 
pathway.  However it is known that Cu2+ binds to FXII and stimulates contact activation, 
driving FXII mediated coagulation156. Soft white china clay is termed Kaolin and has also been 
used since thousands of years as HA. The chief constituent of Kaolin (as in all clays) is hydro-
alumina-silicate (HAS). The negatively charged molecule of HAS activated FXII, which 
induces coagulation. Kaolin forms the basis of the activated partial thromboplastin time 
(aPTT), an assay universally accepted as a measure of “hemostatic competence” and the 
effectiveness of the intrinsic pathway.  
In modern clinical medicine different agents in several ways like hemostatic field dressings, 
topical agents and systemically administered hemostatic agents may improve hemostasis. 
Kaolin is FDA approved as HA in hemostatic field dressings (e.g. Quick-Clot® and Combat® 
gauze). These dressings are well used in civilian prehospital care and conflicts of war 157 and 
has been shown to efficiently induce clotting 158-160. A disadvantage is that Kaolin causes an 
exothermic reaction and pain. Animal studies and a case series of bleeding trauma patients have 
shown thermal injuries, foreign body reactions and fibrosis161, 162. Another silicate based 
hemostatic dressing (WoundStat®) was withdrawn from the market because it caused severe 
endothelial injury and significant trans mural vessel damage. The granules wandered in the 
venous circulation and got trapped in the lung with associated thrombosis163. To summarize, 
silicates are efficient in inducing the contact pathway of coagulation but their side effects can 
be severe. Novel hemostatic dressings with chitosan (polymers of N-acetyl-glucosamine) e.g. 
TraumaStat®, HemCon® and Celox®)164 are vasoconstrictors that adhere to tissues, accelerates 
the concentration of platelets and red blood cells. Chitosan also to activates FXII165 but is not 
biodegradable. Topical Agents (TA) is used in the operating theatre when controls of bleeding 
by standard surgical techniques (suture, ligature or cautery) are ineffective or impractical. 
Thrombin with gelatin (Floseal®, Surgiflow®) converts the patient´s fibrinogen to fibrin. The 
gelatin matrix provides scaffolding for clot formation and swelling for tamponade effect 166, 167. 
A disadvantage with gelatin bound thrombin is that the swelling can cause significant 
compression. Fibrin sealants (TISSEEL, Evicel®) are component mixtures of concentrated 
human fibrinogen, bovine thrombin and calcium, combined by an applicator to form a fibrin 
clot. These are excellent hemostatic devices not depending on patients clotting but require time 
for preparation and are expensive. Fibrin sealant patches (TachoSil®) are biodegradable 
collagen matrix coated with human fibrinogen and thrombin. When in contact with physiologic 
fluid the coating dissolves and diffuses into the tissue and a fibrin clot is formed 168 169. 
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Recombinant FVII (rFVIIa), a systemically administered HA, was developed as a treatment for 
hemophilia patients with antibodies against FVIII and FIX in the 1980s. It´s use in the 
management of traumatic hemorrhage was first described in 1999170 and it has been used in 
both civilian and military trauma since then171, 172. In theory rFVIIa only induces clot formation 
where there is exposure of TF and systemically administered rVIIa should work at the local 
wound site. rFVIIa use has been the subject of randomized controlled trials in trauma patients 
and no benefit in terms of survival has been shown in these studies, although there may be a 
potential benefit in reduction of blood product transfusion and a reduction in the incidence of 
Acute Respiratory Distress Syndrome (ARDS)38, 173. The use of rFVIIa in combat medical 
treatment has declined significantly since early 2010174. Damage Control Resuscitation with 
targeted blood product replacement and the use of bedside thromboelastometry is one likely 
explanation of this trend175. The recognition of arterial thrombosis in connection with rFVIIa 
treatment is another176.  
In the present study the liver was chosen as experimental model, to analyze the hemostatic 
capacity of PolyP, because it has extensively been used as a bleeding-model in previous 
research and hemorrhage from the liver-parenchyma is difficult to control 177, 178. Synthetic 
produced PolyP of similar chain length as in platelets was used to activate the intrinsic pathway 
of coagulation. PolyP efficiently caused hemostasis in grade II liver injuries. The finding that a 
FXII- inhibiting antibody could block PolyP’s thrombin potential indicates that PolyP drives 
thrombin formation by activating FXII. The intrinsic part of the coagulation cascade, which 
adverse effect can induce pathologic thrombus formation, was in this study used for something 
positive, to create local hemostasis 179,180. One of the desired properties of HAs is 
biodegradability to avoid foreign body reactions and bacterial overgrowth. PolyP was degraded 
to an equal rate in blood, plasma and serum but was stable in water and PBS. It can therefore be 
concluded that PolyP is degrade independently of cellular factors, but through enzymes present 
in plasma and serum. Phosphatases normally turn proteins off by de-phosphorylation. One of 
the most common phosphatases in humans is alkaline phosphatase (ALP). The enzyme is also 
detectable in blood and originates predominantly from liver and bone 181,182. It seems 
reasonable to assume that this enzyme is involved in the degradation of PolyP. The 
degradation-pattern of PolyP was the same in swine and human blood and these findings 
confirm previous reports on the labiality of PolyP180, 183. PolyP enhanced the thrombin 
formation, shortened the time to clot formation and increased the clot strength. In vivo it had a 
clear coagulative effect on the bleeding liver injuries and the effect was comparable to the 
effect of Kaolin. It was obvious that the weight of the compression material to a large extent 
was influenced by abdominal fluid. To calculate the true bleeding, the hemoglobin amount in 
each compress was analyzed. SEM also revealed that PolyP stimulated to synthesis of thicker 
fibrin fibrils than both the control and Kaolin. This effect on fibrin fibrils has been documented 
before 184, 185. The fact that PolyP generates thicker fibers than Kaolin might reflect that it acts 
on several levels during fibrin-production whereas Kaolin exclusively activates FXII. PolyP did 
not induce the same inflammatory reaction on the liver tissue, as did Kaolin. Both Kaolin-
treated and PolyP-treated wounds showed signs of edema (increased interstitial space). This 
may be an effect of FXII induced Bradykinin-formation186.  
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The PolyP we used did not optimally adhere to the liver wounds. If PolyP should be taken 
further in the process of developing a new hemostatic agent it needs to be manufactured in a 
way that it adheres better to bleeding surfaces. As is the case with other HAs, PolyP probably 
needs to be coupled to some sort of biodegradable matrix. Another option of using PolyP with 
potent coagulation activity may be to impregnate suture material with the substance, 
minimizing blood loss from suture sites. PolyP shall only be used locally and not be injected 
intravenously since it can cause pulmonary embolism142. 
In summary the present study shows that polyphosphate is effective in initiating coagulation 
and fibrin synthesis in actively bleeding liver wounds. It is degradable in swine and humans 
and it does not cause thermal injuries or inflammation to the extent that Kaolin containing 
hemostatic agents does. The possibility of producing large quantities of polyphosphate at low 
costs could make this an interesting hemostatic device for the future. 
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5. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
Conclusions 
 
Based on Studies I-IV in this thesis the following conclusions were reached: 
 
I. Venoarterial ECMO reduces central venous pressure while maintaining or 
improving systemic perfusion. 
 
II. Targeting FXIIa provides safe anticoagulation in ECMO by inhibiting thrombus 
formation with intact hemostasis. 
 
III. Venoarterial ECMO improves coagulopathy after hemorrhagic shock. 
 
IV. Polyphosphates induces hemostatic coagulation in liver injuries, with minor 
inflammation. 
 
 
Future Perspectives 
 
The care of trauma patients has improved significantly during the last decades. 
Despite this, thousands of people die everyday because of severe trauma and 
sometimes insufficient care. In the developing countries  many lives can be saved by 
improvement of the transport systems, the prehospital care and  the standard of the 
receiving hospitals. In the industrialized world, safety programmes, efficient 
prehospital care, well structured trauma triage and damage control surgery have 
strongly reduced the number of patients dying after injury. However, there are still 
patients dying of hemorrhage and the connected complications. The results presented 
in this Thesis may hopefully contribute to the salvage of patients that earlier has met a 
wasted death after trauma. In the best of worlds our results may also support the 
development of new and safer anticoagulants and thereby reduce the number of 
patients with serious anticoagulant related bleedings. Let us hope so. 
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6. ABBREVIATIONS AND DEFINITIONS 
 
AA Abdominal Aorta 
AAST American Association for the Surgery of Trauma 
Ab Antibiotics or Antibody 
Acidosis Increased acidity in the blood 
ACS Acute Coronary Syndrome 
ACS American College of Surgeons 
ACT Activated Clotting Time 
ADP Adenosine diphosphate 
AF Atrial Fibrillation 
ALP Alkaline Phosphatase 
AMI Acute Myocardial Infarction 
AO Arbeitsgemeinschaft fur Osteosynthesefragen 
APC Activated Protein C, anticoagulant, inactivates FVIIIa and FVa 
aPTT Activated Partial Thromboplastin Time, intrinsic pathway coagulation. 
ARDS Acute Respiratory Distress Syndrome 
AT Antithrombin 
AT III Antithrombin III inhibitor of thrombin, FIXa, Xa, XIa, Heparin target  
ATC Acute Traumatic Coagulopathy 
ATLS Advanced Trauma Life Support 
ATP Adenosine Triphosphate 
AU Australia 
AVCOR ArterioVenous Carbondioxide Removal 
BE Base Excess 
BP Blood Pressure 
Bradycardia Slow heart rate, Low pulse 
BR2 Bradykinin Receptor 2 
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BT Bleeding Time 
C1INH C1 esterase Inhibitor 
C3 Complement factor 3 
C5 Complement factor 5 
CA Canada 
Cannula A tube inserted in the body for removal or infusion of liquid, often blood. 
Cannulation The insertion of a cannula 
Ca2+ Calcium Ion 
CDH Congenital Diafragmatic Hernia 
CFT Clot Formation Time. Time to fibrin polymerization 
CH Switzerland 
Chemotaxis The movement of an organism in response to a chemical stimulus 
CNS Central Nervous System 
Coagulopathy Dysfunctional coagulation ability 
CO Cardiac Output 
CO2 Carbon Dioxide 
Coagulopathy Decreased coagulative/clotting ability INR<1.2, aPTT>35 s 
COT Committee on Trauma 
COX Cyklooxygenase, converts fatty acids to prostanoids 
CPB Cardiopulmonary Bypass 
CPR Cardiopulmonary Resuscitation 
CRRT Continous Renal Replacement Therapy 
CT Clotting Time 
CT Clotting Time. Initiation of clotting. Thrombin Formation 
CT Computed Tomography 
CTI Corn Trypsin Inhibitor 
CVP Central Venous Pressure 
CVPinf CVP in Inferior Vena Cava 
CVPsup CVP in Superior Vena Cava 
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DBP Diastolic Blood Pressure 
DCR Damage Control Resuscitation 
DCS Damage Control Surgery 
DIC Disseminated Intravascular Coagulation 
DO2 Systemic Oxygen Delivery 
DTI Direct Thrombin Inhibitor 
DTSC Definitive Trauma Surgical Care 
DVT Deep Vein Thrombosis 
ECCOR Extracorporeal Carbon Dioxide Removal 
ECMO Extracorporeal Life Support 
ECMO Extracorporeal Membrane Oxygenation 
ECPR Extracorporeal Cardiopulmonary Resuscitation 
ECS Extracorporeal Support 
EDTA Ethylenediaminetetraacetic acid 
ELSO Extracorporeal Life Support Organization 
Endothelium Inner layer of a blood vessel 
ER Emergency Room 
Erythrocyte Red Blood Cell 
etCO2 End tidal carbon dioxide 
ETP Endogenous Thrombin Potential 
EXTEM Extrinsic Thromboelastometry 
F Coagulation Factor 
FAST Focused Abdominal Sonogram for Trauma 
FDP Fibrin Degradation Products 
FEIBA Factor Eight Inhibitor Bypassing Activity 
FFP Fresh Frozen Plasma 
FI Fibrinogen, Adhesive protein that forms the fibrin clot 
Fibrin Protein that stabilizes platelets in blood clots 
Fibrinogen Acute phase protein, cleaved by thrombin to fibrin 
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Fibrinolysis Degradation of fibrin 
FIBTEM Fibrin Thromboelastometry 
FII Prothrombin 
FIIa Thrombin, Activated prothrombin, the main enzyme of coagulation 
FIII Tissue Factor, Thromboplastin, Initiator of extrinsic pathway 
FiO2 Fractional inspired Oxygen Concentration 
FIV Calcium, Metal cation necessary for coagulation reactions 
FIX Christmas factor, enzyme for intrinsic activation of FX 
FV Labile factor, Cofactor for FX to activate prothrombin to thrombin 
FVII Proconvertin, TF and FVIIa initiates extrinsic pathway 
FVIII Antihemophilic factor, cofactor for intrinsic activation of fX 
FX Stuart-Prower factor, activates prothrombin, final common pathway  
FXI Plasma thromboplastin antecedent, intrinsic activator of factor IX 
FXII Hageman factor, initiates intrinsic pathway 
FXIII Fibrin stabilizing factor, transamidase that cross-links fibrin clot 
GP Glycoprotein 
GSW Gun Shot Wound 
HA Hemostatic Agent 
Hb Hemoglobin 
HCT Hematocrit 
HD Hemodialysis 
HFOV High Frequency Oscillatory Ventilation 
Histamine Increases the permeability in capillaries and proteins 
HK High Molecular Weight Kininogen, cofactor for activation of prekallikrein 
HPF High Power Field Image. Quantifies data in Electron Microscopy 
HR Heart Rate 
HSPG Heparan Sulfate Proteoglycan, endothelial cofactor to Antihrombin III 
Hyperfibrinolysis  Increased fibrin degradation 
Hyperlipidemia High lipid levels 
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Hypocoagulable  Reduced coagulation capacity 
Hypoperfusion Reduced perfusion, blood flow 
Hypovolemia Low volume 
Hypotension Low blood pressure 
Hypothermia Low temperature 
IATSIC International Association for Trauma Surgery and Intensive Care 
ICU Intensive Care Unit 
Ig Immunoglobulin 
IJV Internal Jugular Vein 
IL-1/IL-6 Interleukine 1 and 6 
In vitro “In the glass”, tests with cells or biological molecules 
In vivo “Within the living”, tests on living organisms 
INR International Normalized Ratio, a Ratio of prothrombine time 
INTEM Intrinsic Thromboelastometry 
IPPV Intermittent Positive Pressure Ventilation 
ISI International Sensitivity Index 
ISS Injury Severity Score or International Society of Surgeons 
IVC Inferior Vena Cava 
LA Left Atrium 
LAC Lupus Anti Coagulant, Ig that binds to PL and increases clotting 
Leukocyte White blood cell 
LMWH Low Molecular Weight Heparin 
LPK Leukocyt Partikel Koncentration 
LV Left Ventricle 
mAb Monoclonal Ab. Made by identical cells cloned by unique parent cell 
MAP Mean Arterial Pressure or Mean Airway Pressure 
MAS Meconium Aspiration Syndrome 
MASH Mobile Army Surgical Hospital 
MBT Massive Blood Transfusion > 4 PRBC/1h or 50% of blood volume/3h 
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MCF Maximum Clot Firmness. Clot stabilization by Fibrin, PLT and FXIII 
MEDEVAC Medical Evacuation, evacuation of a patient from the battlefield 
ML Maximum Lysis. Stability of the Clot or Fibrinolysis 
mL Milliliter 
mm Hg Millimeter Mercury (pressure unit) 
MOF Multi Organ Failure 
Monocyte Leukocyte in the immune system, can differentiate to a macrophage 
MRI Magnetic Resonance Imaging 
NICU Neonatal Intensive Care Unit 
NIV Non Invasive Ventilation 
NO Nitric Oxide, powerful vasodilator with halflife of seconds 
Noradrenaline Increases Heart rate and Blood pressure during stress 
O2 Oxygen 
OI Oxygenation Index 
OR Operating Room 
OT Operating Theatre 
PA Pulmonary Artery 
PAF Platelet Activating Factor initates platelet-aggr. and degranulation 
PAI-1 Plasminogen Activator Inhibitor 1 
Part.thrombopl. Partial thromboplastin. Phospholipids without TF 
PC Protein C 
PCC Prothrombine Complex Concentrate. FII, FVII, FIX and FX 
PCO2 Partial Pressure of Carbon Dioxide 
PDGF Platelet Derived Growth Factor 
PE Pulmonary Embolism 
PEA Pulseless Electric Activity 
PEEP Positive End Expiratory Pressure 
PEG PolyEthylene Glycol 
PEO PolyEthylene Oxide 
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Perfusion The passage of a fluid through a vessel or an organ 
PGE2 Prostaglandin E 2, Direct vasodilator 
PGI2 Prostacyclin, Anticoagulant, Vasodilator and Platelet Act. Inhibitor 
Phage Display A technique to find Ab:s that fit certain proteins, e.g coag. factors 
PHT Pulmonary Hypertension, PA pressure > 25 mm Hg 
PICU Pediatric Intensive Care Unit 
PK Plasma Kallikrein 
PL Phospholipid 
PLT Platelet, Thrombocyte 
PO2 Partial Pressure of Oxygen 
PP Pulse Pressure (SBP-DBP) 
PPK Plasma Prekallikrein, Fletcher factor, initiation of intrinsic pathway 
Pport Pressure in Portal Vein 
PPP Platelet Poor Plasma 
PRBC Packed Red Blood Cells 
Prostacyclin PGI2 Active in the resolution phase of inflammation 
Prostaglandin Mediator of inflammation and Anaphylaxis 
Prostanoids Prostacyklins, prostaglandins and thromboxanes 
Protein C Anticoag Act. to APC, downreg Thrombin, cleaves FVa and FVIIIa 
Protein S Cofactor for Protein C 
PT Pro-thrombin Time, measures the extrinsic pathway of coagulation 
PVC Poly Vinyl Chloride 
Qport Flow in portal vein 
RA Right Atrium 
RCT Randomized Clinical Trial 
Recombinant A product of genetic engineering 
Ref. Reference 
ROTEM Rotational Thrombolestometry 
RPM Revolutions Per Minute 
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RR Respiratory Rate 
RV Right Ventricle 
SBP Systolic Blood Pressure 
SBT Skin Bleeding Time 
SEM Scanning Electrone Microscopy 
SER Serotonin 
Serine Aminoacid 
Serine protease Enzyme that cleave proteinbonds were serine is in the active site 
Sic! Sic erat scriptum. It is true! 
SIRS Systemic Inflammatory Response Syndrome 
SO2 Arterial oxygen saturation 
STRATEVAC Strategic Evacuation, evacuation of patient to another country 
SVC Superior Vena Cava 
SVO2 Mixed Venous Oxygen saturation 
TA Topical Agent 
Tachycardia High heart rate, Fast pulse 
Tachypne High respiratory rate 
TAFI Thrombin Activatable Fibrinolytic Inhibitor 
TCR Trans Capillary Refill 
TEG Thrombolestography 
TEM Thromboelastometry 
TF Tissue Factor 
TFPI Tissue Factor Pathway Inhibitor, Inhibits the TF/FVIIa complex 
Thrombocyte Platelet 
Thrombokinase Converts prothrombin toThrombin 
Thrombomodulin A cofactor for thrombin induced act. of protein C to anticoag. APC 
Thromboplastin FIII, Tissue Factor (TF) 
TIC Trauma Induced Coagulopathy 
TNF Tumour Necrosis Factor 
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tPA tissue Plasminogen Activator 
TPK Trombocyt Partikel Koncentration, Platelet count 
TVE Total Vascular Exclusion 
TXA2 Thromboxane A2, vasoconstrictor 
UK United Kingdom 
UNFH Unfractionated Heparin, “Heparin” 
UO Urinary Output 
USA United States of America 
USG UltraSonoGrapghy 
VA Venoarterial 
VAD Ventricular Assist Device 
Vasopressor Antihypotensive agent 
VAV Venoarteriovenous 
Western Blot Method to detect proteins in tissue samples, gel-electrophoresis + Ab:s 
VO2 Systemic oxygen consumption 
VTE Venous Thromboembolism 
VV Venovenous 
VVA Venovenoarterial 
vWD von Willebrand Disease 
vWF von Willebrand Factor 
WWI World War I 
WWII World War II 
ZA South Africa (Republiek Zuid-Afrika) 
Zymogen Proenzyme, Inactive enzyme precursor 
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“Factus est Dominus protector meus”  
 
 
 
 
 
 
 
 
 
 
 
 
 
In the early morning, on the 17th of June 1682, at Stockholms Castle, 
Queen Ulrika Eleonora gave birth to a Prince with a caul 
“segerhuva”. He was to become King Karl XII, responsible for even 
more blood shed on the soil of northern Europe...  
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